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Abstract
Subthalamic (STN) deep brain stimulation (DBS) is an established treatment to alleviate the
appendicular motor symptoms of Parkinson's Disease (PD). Current steering during DBS
allows the unequal fractionation of current between two electrodes on the lead, resulting in a
non-spherical electrical field. It is hypothesized that the way the electrical field is shaped will
affect a patient’s upper limb symptom alleviation. Seven PD patients who underwent
bilateral STN-DBS were tested over four weeks post-operation. 16 current fractionation
settings were tested each week at an amplitude that increased weekly. Optimal setting was
defined as the setting that provided the best symptom improvement based on kinematic data
detected by a motion capture system and the Unified Parkinson's Disease Rating Scale.
Results assessing right and left upper limb symptoms gave 14 optimal settings in seven
patients, of which eight settings employed current steering either unilaterally or bilaterally,
and six settings employed bilateral monopolar stimulation. Thus, the use of current steering
was patient-dependent and limb-dependent; factors contributing to this finding include
differences in lead placement, symptom heterogeneity, and possible differences in STN
functionality.

Keywords
Parkinson’s disease, deep brain stimulation, current steering, motor symptoms, appendicular
symptoms, upper limb, electrical field, current fractionation
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Chapter 1
1

Introduction

The current thesis investigates the effects of current steering during deep brain
stimulation of the subthalamic nucleus on the appendicular motor symptoms of
Parkinson’s disease. This chapter lays down the foundation of Parkinson’s disease,
exploring its etiology and the available treatment. An in-depth review on deep brain
stimulation will be presented, focusing on different targets in the brain and the
technology used for stimulation. Next, the pathophysiology of the three main
appendicular motor symptoms—bradykinesia, tremor, and rigidity—will be detailed,
followed by the study rationale and objectives.
1.1

Parkinson’s disease: overview and etiology

Parkinson’s disease (PD) was first medically described by James Parkinson in 1817 in his
short monograph “An Essay on the Shaking Palsy” (Parkinson 1817). It is a progressive
neurodegenerative disease characterized by motor and non-motor symptoms (DeMaagd
& Philip, 2015). The cardinal motor features include resting tremor, muscular rigidity,
and bradykinesia, which are often reported as the first clinical findings of the disease
(DeMaagd & Philip, 2015). Although the cardinal features mainly affect the appendages
of the body, PD also includes axial symptoms such as dysarthria, gait dysfunction, and
postural instability (Bejjani et al., 2000). Nonmotor presentations of the disease have
been stated to occur before the onset of motor symptoms and include sleep disorders,
depression, and cognitive changes (DeMaagd & Philip, 2015).
PD is one of the most common neurodegenerative diseases, with an incidence in the U.S.
of approximately 60,000 cases per year and a prevalence of approximately 1% in people
60 years of age and older (DeMaagd & Philip, 2015). With the mean age of onset close to
60 years, PD is primarily a disease of the elderly although individuals have developed the
disease as early as their 30s. There are gender differences in the incidence of PD,
emphasized by the 3:2 ratio of males to females, with a delayed onset in females
potentially due to the neuroprotective effects of estrogen (DeMaagd & Philip, 2015).

2

The pathophysiological hallmark of PD can be characterized by two processes: (a) the
loss of dopaminergic neurons in the pars compacta of the substantia nigra (SNc); (b) the
presence of Lewy bodies, composed of α-synuclein, which become misfolded and
accumulate in surviving neurons of the SNc and other brain regions (Connolly & Lang,
2014). There is 30-70% cell loss in the SNc when motor symptoms of PD become
evident (Rizek, Kumar, & Jog, 2016). Dopamine deficiency is said to be the predominant
neurochemical abnormality, with the involvement of nondopaminergic brain regions as
the disease progresses (Connolly & Lang, 2014). Cognitive dysfunction, mood disorders
and impulse control disorders observed in PD patients are related to a dopamine
deficiency outside the basal ganglia or in serotonergic and noradrenergic systems (Rizek
et al., 2016).
1.1.1

The classical model of basal ganglia function in PD

The basal ganglia include the striatum,—which comprises the caudate nucleus, putamen,
and nucleus accumbens— the globus pallidus which contains an internal segment (GPi)
and external segment (GPe), the substantia nigra which can be divided into the SNc and
substantia nigra pars reticulata (SNr), and finally the subthalamic nucleus (STN) (Obeso
et al., 2000). Together with cerebral regions and the thalamus, the basal ganglia form a
complex network of circuits (Figure 1a); the motor circuit is most directly related to the
pathophysiology of movement disorders including PD (Obeso et al., 2000). Cortical
motor areas project in a somatotopic fashion to the putamen where they form excitatory,
glutamatergic connections with medium spiny neurons containing γ-aminobutyric acid
(GABA); these neurons give rise to the direct and indirect pathways that connect the
striatum to the output nuclei of the basal ganglia, namely the GPi and SNr (Obeso et al.,
2000). Neurons in the direct pathway project directly from the putamen to the GPi/SNr,
they contain dopamine D1 receptors, and provide a direct inhibitory effect on GPi/SNr
neurons (Obeso et al., 2000). Neurons in the indirect pathway connect the putamen with
the GPi/SNr via synaptic connections in the GPe and STN and they contain dopamine D2
receptors (Obeso et al., 2000). Activation of neurons in the direct pathway leads to
reduced neuronal firing in the GPi/SNr while activation of neurons in the indirect
pathway leads to inhibition of the GPe, disinhibition of the STN, and excitation of the
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GPi/SNr (Obeso et al., 2000). Thus, the direct and indirect pathways have opposing
effects on basal ganglia output with the activation of neurons in the direct pathway
facilitating motor activity, and activation of the indirect pathway suppressing motor
activity (Obeso et al., 2000). In a normal brain, the model proposes that dopamine from
the SNc exerts a dual effect on striatal neurons by exciting D1-receptor-expressing
neurons in the direct pathway and inhibiting D2-receptor-expressing neurons in the
indirect pathway (Obeso et al., 2000). In PD, dopamine deficiency causes increased
activity in the indirect circuit and reduced activity in the direct circuit. Although an
oversimplification, the imbalance between the direct and indirect striatal pathways partly
provides an explanation for the cardinal symptoms of PD. A schematic representation of
the classical model of basal ganglia function in the normal and parkinsonian state is
shown below (Figure 1; Obeso et al., 2000).

© Elsevier. Adapted with permission.

Figure 1: Schematic representation of the classical model of basal ganglia function
in the (a) normal and (b) parkinsonian states
Blue arrows depict inhibitory projections and red arrows depict excitatory projections;
thickness of arrow signifies the degree of activation. Direct pathway connects the
putamen with the output nuclei (globus pallidus pars interna (GPi) and substantia nigra
pars reticulata (SNr)) directly and the indirect pathway contains synaptic connections in
the globus pallidus pars externa (GPe) and subthalamic nucleus (STN). (a) In the normal
state, dopamine inhibits neuronal activity in the indirect pathway and excites neurons in
the direct pathway. (b) In PD, dopamine depletion leads to disinhibition of striatal
neurons in the indirect pathway, leading to increased inhibition of the GPe and
disinhibition of the STN; overactivity of the STN leads to excess excitation of GPi/SNr
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neurons and overinhibition of thalamo-cortical motor centers. SNc: substantia nigra pars
compacta; PPN: pedunculopontine nuclei; VL: ventral lateral thalamus.
The goal of therapy aims to replace dopamine with dopaminergic medications to
modulate the dysfunctional circuit in the basal ganglia. Although there is no established
cure or disease-modifying therapies (Connolly & Lang, 2014), there are treatments to
improve the quality of life for PD patients. There is strong evidence to support the use of
levodopa and dopamine agonists at all stages of PD to treat motor symptoms, levodopa
being the most effective medication (Connolly & Lang, 2014). Levodopa is transported
from the peripheral circulation across the blood-brain barrier and is converted to
dopamine in the striatum where it exerts its dopaminergic effects. Although levodopa is
prescribed to treat almost all motor symptoms, its adverse effects can hinder the
symptomatic benefit gained by patients. The adverse effects of levodopa include nausea,
orthostatic hypotension, hallucinations and motor complications such as motor
fluctuations and dyskinesia (Connolly & Lang, 2014). Motor fluctuations are alterations
between “on” and “off” periods; on periods are when patients experience a good response
to medication and off periods are when the benefit from medication wears off and
symptoms re-emerge (Connolly & Lang, 2014). Dyskinesia is defined as involuntary
movements correlated to fluctuations in dopamine levels and can lead to impaired motor
function and injury. Motor fluctuations are unexpected variations in the motor response
to dopaminergic therapy whereas dyskinesias are unwanted and intrusive movements
caused by levodopa (Rizek et al., 2016). In 40%-50% of patients, motor fluctuations and
dyskinesias will develop within five years of chronic levodopa treatment and after 10
years of levodopa treatment in 70%-80% of patients (Rizek et al., 2016). Catechol Omethyltransferase (COMT) inhibitors, monoamine oxidase B inhibitors and dopamine
agonists may be prescribed to reduce off periods. Reduction of dopaminergic medication
can reduce the severity of dyskinesia; however, this will cause re-emergence of PD
symptoms. For this reason, medications such as Amantadine, an antiviral with
antiglutamatergic effects, and Clozapine are prescribed to improve dyskinesia (Connolly
& Lang, 2014). Some patients require a combination of different types of medication for
symptom management and thus require a highly regimented schedule for medication
intake. Levodopa’s short half-life results in fluctuations in levodopa plasma
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concentration, causing the efficacy of levodopa to decline due to the emergence of
dyskinesia and motor fluctuations (Rizek et al., 2016). As a result, many PD patients look
to neurosurgical interventions for managing their symptoms. The classical model of basal
ganglia function and its prediction of increased STN and GPi activity in PD can be used
to justify the efficacy of targeting these two nuclei with deep brain stimulation (DBS),
which represents the gold standard of treatment for motor fluctuations and dyskinesia in
advanced PD (Magrinelli et al., 2016).
1.2

Deep brain stimulation for PD

DBS is widely accepted as a treatment option for PD, dystonia, tremor, and is less known
as a treatment for many other movement disorders (Fasano & Lozano, 2015). For PD, a
consistent and sustained improvement in motor function and quality of life can be
achieved through DBS (Fasano & Lozano, 2015). DBS works by sending an electrical
current through a set of electrodes attached to a lead; the lead is placed within a target
region—which differs according to the diagnosis—inside the brain. The lead is attached
to the pulse generator, implanted in the chest region, through a wire that runs
subcutaneously. Candidates for DBS to treat PD require a disease duration of at least 5
years and clear and significant response to levodopa is considered as a favorable
predictor for surgery (Broggi, Franzini, Marras, Romito, & Albanese, 2003). Other
inclusion criteria include: (1) idiopathic PD, (2) stage II or IV on the Hoehn-Yahr scale
(rates the severity of PD in five levels, with I being the mildest), (3) severe motor
fluctuations, (4) no dementia or psychiatric abnormalities (Broggi et al., 2003).
In PD, DBS usually involves bilateral stimulation in either the STN or the GPi. The
motor benefits are similar with each target, but the number of publications and size of
clinical experience is greater for STN DBS (Fasano & Lozano, 2015). There is evidence
pointing to differences between STN and GPi as the target with regards to specific
symptoms and features of PD. The STN is favored for greater benefit in the severity of
off symptoms and also contains a cost advantage; reduction in PD medication is only
seen after STN DBS and given the smaller size of the STN, the charge density required
for stimulation is lower and therefore leads to less battery usage than for GPi stimulation
(Fasano & Lozano, 2015). Appendicular symptoms respond better to STN stimulation
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and axial motor symptoms respond better to GPi stimulation (Fasano & Lozano, 2015).
Specifically, studies have pointed towards favoring STN stimulation for rigidity and
bradykinesia, although no difference between targets was seen for tremor (Fasano &
Lozano, 2015). Dyskinesia suppression and long-term effects on stability and cognition
favor GPi (Fasano & Lozano, 2015). Because the long-term outcome is better known for
STN DBS, it is viewed by many as the ultimate therapy targeting advanced stages of PD
(Romanelli, Bronte-Stewart, Heit, Schaal, & Esposito, 2004).
1.2.1

Stimulation technology

The first commercially available DBS system was manufactured by Medtronic in 1976
(Kopell, Machado, & Butson, 2009). Since then, DBS therapy has come a long way with
constant modifications to the implantable pulse generator (IPG) and lead that make up the
neurostimulation system. IPGs can be programmed for adjustments in current amplitude,
pulse width, and frequency, as well as for the activation of individual contacts on the lead
as cathodes or anodes. IPGs were initially limited in frequency output to 185 Hz and
pulse widths longer than 500 µs are rarely used (Kopell et al., 2009). The stimulation
amplitude ranges from 0 to 25 mA in different devices (Kopell et al., 2009). In PD, most
clinical DBS studies have found frequencies in the range of 143 to 173 Hz, pulse widths
in the range of 67 to 138 µs, and amplitudes in the range of 2.4 to 4.4 V effective in
controlling motor symptoms (Wagle Shukla, Zeilman, Fernandez, Bajwa, & Mehanna,
2017). Before discussing the difference between voltage-controlled systems and currentcontrolled systems, as well as monopolar and multipolar stimulation, a better
understanding of the mechanisms underlying the therapeutic effects of DBS can be
achieved by investigating the functional organization of the STN.
1.2.2

Functional organization of the STN

Recent research has pointed at the STN as an input structure into the basal ganglia – a
control center for motor and cognitive behavior (Tewari, Jog, & Jog, 2016). The basal
ganglia are subdivided into three functional units; the motor, associative, and limbic
cortical regions innervate, respectively, motor, associative, and limbic regions of the
striatum, pallidum, and substantia nigra pars reticulata (SNr) (Hamani, Saint-Cyr, Fraser,
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Kaplitt, & Lozano, 2004). A similar functional subdivision has been applied to the STN
based on cortical projections (Tewari et al., 2016). The dorsolateral STN contains the
sensorimotor region; direct projections from the primary motor cortex and supplementary
motor area (SMA) are received here. The ventromedial STN contains the associative
region with projections from the premotor cortex, prefrontal cortex, pre-SMA, SMA,
frontal eye field, and supplementary eye field (Tewari et al., 2016). The limbic region is
located in the medial tip of the STN, receiving projections from the caudal cingulate
motor area (Figure 2; Tewari et al., 2016).

© Frontiers Media. Adapted with permission.

Figure 2: Subthalamic Nucleus (STN) subdivision into three functional units; the
sensorimotor, associative, and limbic regions
Cortical inputs into each region depicted by individual arrows. SMA: supplementary
motor area; M1: primary motor cortex; PFC: prefrontal cortex; FEF: frontal eye field;
SEF: supplementary eye field; PMC: premotor cortex.
The purpose of investigating the functional organization of the STN is to determine if
there is an optimal stimulation site for DBS. There is evidence to show that the
dorsolateral STN border is included in the optimal stimulation site – which is valid since
the dorsolateral portion is the sensorimotor region with inputs from motor cortical areas.
Included in the evidence pointing towards this conclusion is a study by Herzog and his
colleagues who evaluated the optimal stimulate site in 14 patients treated by bilateral
STN-DBS (Herzog et al., 2004). The position of the most effective contact on a
quadripolar electrode lead was evaluated using preoperative magnetic resonance imaging
(MRI) scans, electrophysiological recording, and postoperative stereotactic x-ray images
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(Herzog et al., 2004). The best clinical results with the least energy consumption were
found in contacts located in the dorsolateral border zone, whereas contacts within the
STN white matter were significantly less effective (Herzog et al., 2004). Although the
study does not provide a mechanism for DBS, it reinforces the relevance of the
neighboring structures at the dorsolateral STN boundary in alleviating parkinsonian
symptoms (Herzog et al., 2004).
1.2.3

Fundamentals of neuronal stimulation

Defining the response of the neural elements, near the site of the electrode, to the applied
electric field can contribute to the understanding of the effects of DBS. The DBS electric
field is a three-dimensionally complex phenomenon that is generated by the redistribution
of charged ions in the extracellular space of neurons (McIntyre & Anderson, 2016). Since
the 1960s, an upheld view was that the primary effect of electrical stimulation in the brain
was the generation of action potentials. The action potential is a change in the electrical
potential across the neuronal membrane caused by the flow of electrical charges
(Montgomery Jr., 2017). DBS works by depolarizing the neural membrane to reach the
activation threshold for action potential generation. The axon of a neuron has the lowest
threshold for activation; therefore DBS exerts its effects in the axon at the actionpotential-initiating-segment, which is typically (but not necessarily) the axon hillock
(Montgomery Jr., 2017). An action potential can propagate in both directions; the action
potential moving toward the synapse is traveling orthodromically, which is typical in
biological systems, whereas the action potential moving in the opposite direction toward
the cell body or soma is travelling antidromically. Antidromic activation has important
physiological implications and may mediate the therapeutic effects of DBS. Research has
shown that stimulation of the GPi activates axons from the ventral thalamus pars oralis,
causing antidromic activation of thalamic neurons (Montgomery Jr., 2017). This goes to
show how the effects of stimulation can propagate widely beyond the local site of the
DBS active contact. In addition to the composition of neural elements that make up the
stimulation target, other factors also determine the effects of stimulation including the
afferent and efferent pathways associated with the target and the amplitude, pulse width
and frequency of the applied current (Laxton, Dostrovsky, & Lozano, 2009). Given that
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electrical stimulation can spread to affect neural elements outside of the immediate
nucleus being stimulated, one might argue that STN or GPi stimulation is a way of
labeling where the electrodes are placed to deliver electrical pulses as opposed to using it
as a convention for the stimulation of a specific nucleus. Although there is evidence to
show the neuronal responses to DBS, insight into the therapeutic mechanisms and
specifically, why targets such as the STN and GPi provide clinical benefit remains
unclear. A growing number of studies have been conducted to investigate whether the
therapeutic action of DBS is an excitatory or inhibitory nervous system response.
1.2.3.1

Does DBS elicit an inhibitory or excitatory response?

Although evidence points to DBS pulses causing the generation of action potentials in
axons near the electrode, other theories argue in favour of reduced neuronal firing. Due to
the observation of similar clinical effects, it is possible that DBS and surgical lesions
share a similar mechanism of action through the inhibition of neuronal activity (Laxton et
al., 2009). One potential way of carrying out neuronal inhibition is through the alteration
of cellular and membrane properties by the application of high frequency stimulation
(HFS) (Laxton et al., 2009). An in vitro study found that HFS decreases the excitability
of neurons in the rat STN through inactivation of voltage-gated sodium and calcium
currents (Beurrier, Bioulac, Audin, & Hammond, 2001). Therefore, HFS shows the
ability to block depolarization by transiently depressing calcium channels (Beurrier et al.,
2001). Another study showed that HFS causes increased extracellular potassium levels in
rat hippocampal slices (Bikson et al., 2001). These elevated potassium levels depolarize
the neuron to produce a depolarization block. Persistent membrane depolarization
induces this depolarization block, which results in the inactivation of voltage-gated
sodium channels and by extension, prevents action potentials (Bikson et al., 2001). The
application of in vitro findings to the understanding of DBS effects is somewhat trivial
due to the fact that current densities in animal studies are much higher than those used in
human DBS and the slice preparations lack many of the connections and pathological
activity patterns that exist in human PD patients (Laxton et al., 2009).
A study using human PD patients found that stimulation at high frequencies (100-300
Hz) can decrease the firing rate in STN neurons that are 600 microns away from the
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stimulation site (Filali, Hutchison, Palter, Lozano, & Dostrovsky, 2004). Furthermore,
another study showed that low frequency microstimulation (5 Hz) within the GPi caused
inhibition of GPi neurons lasting a duration of 10-25 ms (Dostrovsky et al., 2000).
Although studies of HFS suggest that stimulation inhibits neuronal activity, other studies
have shown that the effect of stimulation is variable and can be excitatory (Laxton et al.,
2009). Electromyographic responses to HFS of the STN that were analyzed in 14 patients
with parkinsonism did not reveal evidence for stimulation blocking neuronal activity;
rather, the ability of HFS to reduce tremor in the contralateral limbs of five patients
resulted from the activation of large-diameter axonal fibers (Laxton et al., 2009). One
way to reconcile these differences in study conclusions is to keep in mind that DBS may
be a chemical therapy; depending on the specific pathway being stimulated, the
downstream effect could be inhibitory via modulated GABA release or excitatory via
modulated glutamate release (McIntyre & Anderson, 2016). Therefore, when HFS is
excitatory, the effect can be on GABAergic axons which eventually reduces the neuronal
firing rates in the STN or GPi to have an inhibitory influence (Laxton et al., 2009). For
example, direct stimulation of the GPe axonal afferents can theoretically generate GABA
release in the STN through antidromic activation, thus having a possible inhibitory effect
on STN efferents.
Local field potentials (LFPs) recorded from the basal ganglia can provide insight
regarding the mechanisms of DBS. LFPs indicate the oscillatory activity of a neuronal
population surrounding the recording electrode and can be categorized according to
specific frequency bands (Wagle Shukla et al., 2017). Beta band oscillations contain a
frequency range between 11 Hz and 30 Hz and excessive synchronization of basal
ganglia neuronal activity in the beta frequency band has been implicated in some forms
of PD (Eusebio & Brown, 2009). Bronte-Stewart and colleagues recorded LFPs
intraoperatively from the STN and showed excessive synchronization at beta frequencies
at rest in 16 PD patients undergoing DBS (Bronte-Stewart et al., 2009). The study also
showed suppression of beta activity with attenuation lasting for 10 seconds after 30
seconds of DBS and for up to 50 seconds after five minutes of DBS; this finding suggests
there may be long-acting functional changes to basal ganglia networks in PD after
chronic DBS (Bronte-Stewart et al., 2009). However, several studies have led to the
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general consensus that beta synchrony is not causally linked to parkinsonian tremor but
could be a good biomarker of the akinetic-rigid state in both patients and animal models
of parkinsonism (Eusebio & Brown, 2009).
1.2.4

Monopolar and multipolar stimulation

Four electrical contacts on the typical DBS lead allow for a large combination of active
contacts and by extension, different fields of electrical current coming in contact with
neural elements (Montgomery Jr., 2017). Within the DBS target, the combinations of
active contacts can be divided into monopolar or multipolar (Montgomery Jr., 2017).
Monopolar refers to the active contact within the stimulated structure being negative
(cathode) whereas the positive contact (anode) is the IPG itself. Multipolar configurations
have more than one active contact within the stimulated structure which can include both
negative and positive contacts (Montgomery Jr., 2017). A bipolar (type of multipolar)
configuration has a single negative and single positive contact in the DBS target
(Montgomery Jr., 2017).
1.2.5

Current-based programming and current steering

IPG output can be a voltage-controlled or, more recently, current-controlled system.
Current-controlled systems adjust the voltage for a given impedance in order to deliver a
constant current output (Kopell et al., 2009). Voltage-controlled systems automatically
adjust the current to compensate for impedances (Kopell et al., 2009). Although for
several years DBS therapy involved voltage-controlled systems, the fluctuations in
impedance values at the electrode-tissue interface cause an instability in the
electrical charge delivered to the target. Low impedance values could cause high current
densities at the electrode-tissue interface and result in possible tissue damage (Kopell et
al., 2009). High impedance values result in a large voltage drop at the electrode-tissue
interface and decrease the effectiveness of stimulation (Kopell et al., 2009). The clinical
results from current-controlled systems are less subject to changes in impedances over
time because the voltage gets automatically adjusted (Kopell et al., 2009). As a result,
DBS programming is more effective and reliable with current-controlled systems.
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Conventional DBS technology relied on a single current source to produce an electrical
field that is spherical; this causes limited capability to minimize unintended current
spread to anatomical structures that can cause side effects. Both the clinical effects and
side effects caused by stimulation depend on the direction and amount of current spread
to neighboring anatomical structures (Wagle Shukla et al., 2017). As discussed, the
optimal location for STN stimulation is the dorsolateral region for control of motor
symptoms. Medial spread of current from the dorsolateral region can stimulate the limbic
region of the STN, cranial nerve III and the red nucleus, causing side effects such as
diplopia, eye deviation, dizziness, sweating, nausea, paresthesia, warm sensation,
depression and impulsivity (Wagle Shukla et al., 2017). Lateral spread of current can
stimulate the corticospinal tract and frontal eye field fibers of the internal capsule,
causing facial pulling, limb contraction and contralateral deviation of gaze (Wagle Shukla
et al., 2017). Posterior spread of current can stimulate the medial lemniscus and cause
paresthesia (tingling, electrical sensation, numbness) and ventral/inferior spread of
current can stimulate the SNr and internal capsule fibers, causing mood changes,
depression and muscle contractions (Wagle Shukla et al., 2017). As a result, clinical
benefit with minimal side effects can only be achieved by steering current away from
these structures. Newer systems with multiple independent current sources makes it
possible to fractionate current amplitude between two or more active contacts on a lead –
a phenomenon known as current steering (Timmermann et al., 2015). DBS devices that
allow the fractionation of current using a type of multipolar configuration enables the
application of a shaped electrical field (Timmermann et al., 2015). This means that
combinations of different percentages allow for differences in electrical field shape
(Figure 3; Barbe, Maarouf, Alesch, & Timmermann, 2014). This shaped electrical field
can possibly enhance the motor response of patients while minimizing stimulation-related
side effects. The Vercise DBS system by Boston Scientific is a current-controlled system
that allows for current steering. The Vercise lead consists of eight contact rings, 1.5 mm
in length, placed one above the other with 0.5 mm spacing between contacts
(Timmermann et al., 2015). Given the numerous combinations available for current
amplitude fractionation which lead to many different electrical field shapes, current
steering is part of the advancement to a more individualized form of DBS therapy. An
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overview of present literature investigating the effects of current steering is discussed
below.

© Elsevier. Used with permission.

Figure 3: Altered electrical field shape using current steering
Electrode location shown in anatomical relation to the thalamus (yellow), STN (green),
and red nucleus (maroon). A: 100% of the current amplitude delivered from contact #2 is
a monopolar stimulation creating a spherical electrical field (red). B: Current amplitude
fractionation over two contacts shifts current field (red) more dorsally. C: Current
amplitude fractionation over the bottom three contacts (10% on contact #1, 75% on
contact #2, 15% on contact #3) produces a non-spherical electrical field (red). D: Current
amplitude fractionation over four contacts further elongates the electrical field (red) to
stimulate more dorsal structures such as the zona incerta.
1.2.5.1

Studies investigating current steering during STN-DBS

The available literature on clinical trials that investigate the effectiveness of current
steering is limited due to the relatively recent introduction of current steering DBS
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devices into the market. Most studies have either focused on the safety and efficacy of the
new DBS system or have used computational modeling to predict the volume of tissue
activated with current steering, but few have directly tested current steering settings on
PD patients undergoing STN-DBS. One of the most cited studies in this area is the
VANTAGE study; a multicenter, non-randomized clinical trial evaluating the multiplesource, constant-current Vercise DBS system by Boston Scientific. 40 PD patients who
underwent bilateral STN-DBS were assessed 12, 26, and 52 weeks after implantation; the
primary endpoint was the mean change in Unified Parkinson’s Disease Rating Scale
(UPDRS) motor scores from baseline to 26 weeks after implantation in the stimulationon, medication-off state (Timmermann et al., 2015). The treating clinician identified the
contact that provided the best clinical effect and in the case of side effects or absence of
efficacy, current was fractionalized over the ideal contact and the next best contact
(Timmermann et al., 2015). PD patients significantly improved by 62.6% (+/- 19.8) when
comparing baseline UPDRS motor scores with six month postoperative scores. At 26 and
52 weeks post implantation, approximately 70% of stimulation programs had current
fractionalized over two or more contacts. The remaining programs used a monopolar
configuration. This study shows that in the case of suboptimal DBS therapy, the use of
current steering across two or more contacts can be used to suppress motor symptoms
more effectively than monopolar configurations.
A case study published in 2014 was the first report showing the effects of multiple source
current steering in humans. The case focused on a single patient, a 60-year-old male
diagnosed with PD for 13 years, who was treated with bilateral STN-DBS with the
Vercise DBS system. Before surgery, he had a levodopa response of almost 80% based
on UPDRS motor scores, however medications resulted in severe dyskinesia resulting in
social life exclusion (Barbe et al., 2014). One week after implantation, the left lead was
programmed with a monopolar stimulation setting, whereas the right lead needed more
fine tuning with current steering. A standard monopolar review is a post-operative
programming strategy that individually tests each stimulation contact on a lead by
increasing current amplitude in small increments to test for symptom improvement or any
adverse effects. After going through a series of possible settings, the patient was set on an
overall current amplitude of 5.9 mA on the right STN lead, fractionalized over the bottom

15

four contacts. Contact #2 (from ventral to dorsal) received 50% current stimulation
because the monopolar review identified this contact as producing the best therapeutic
effect, however further increasing amplitude on contact #2 induced dyskinesia (Barbe et
al., 2014). Contact #3 received 10% current stimulation to reshape the field and maintain
the clinical effect of contact #2 (Barbe et al., 2014). Contact #4 received 30% current
stimulation because the authors assumed further improvement in tremor and dyskinesia
was due to the stimulation of the zona incerta (for tremor alleviation) and pallidofugal
fiber tracts (for dyskinesia alleviation) located dorsal to the STN (Barbe et al., 2014).
Contact #1 received 10% current stimulation because the patient continued to experience
some apathy and the authors hypothesized that improvement of apathy with contact #1
stimulation was due to targeting of the limbic STN (Barbe et al., 2014). With this current
steering setting, the patient’s UPDRS motor score improved from 45 points before
therapy to 15 points with DBS and their levodopa dose decreased by 70% three months
after surgery (Barbe et al., 2014). Over two years after the surgery, the patient was still
reporting excellent results including clear speech, good gait, excellent postural reflex, no
rest tremor and only tiny action tremor (Barbe et al., 2014). Overall, this case report
showed that current steering minimized side effects and led to a good reduction of all PD
motor symptoms.
A pilot study using a novel directional DBS device was published in 2016 to evaluate the
effects of current steering in horizontal directions. Seven PD patients implanted with the
novel directional lead underwent bilateral STN-DBS; the novel lead has four electrode
levels with the two middle levels split into three segments spanning approximately 120
degrees (Steigerwald, Müller, Johannes, Matthies, & Volkmann, 2016). Each segment is
capable of independent stimulation such that 100% of current amplitude is capable of
being delivered from approximately one third of the contact ring. An extended monopolar
review during the first postoperative week determined a therapeutic window for 111
directional settings and 24 ring-mode settings across the seven patients. Although there
was high variability between leads and directional settings, there was a general trend of
an expansion of the therapeutic window with the directional settings (Steigerwald et al.,
2016). Overall, this study shows the effects of directional current steering in the
expansion of the therapeutic window during monopolar review, as compared to ring-
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mode stimulation. The benefits of directional stimulation were best appreciated in cases
of suboptimal electrode positions resulting in a narrow therapeutic window. Suboptimal
lead positioning can occur at any stage during the DBS procedure.
1.3

STN-DBS procedure

The DBS procedure might vary between neurosurgical teams with regards to equipment,
however the surgical techniques are similar. The planning of the procedure starts off by
using pre-operative MRI scans, which are used to construct the stereotactic target using
graphic tools and various atlases that are available on navigation software (Benabid,
Chabardes, Mitrofanis, & Pollak, 2009). The planning stage allows surgeons to choose an
entry point that will avoid puncturing vessels, including those located at the cortical
surface, ventricle, or caudate nucleus. With the patient in a stereotactic head frame, the
anterior and posterior commissures are identified; STN coordinates are based on a
stereotactic brain atlas at 12 mm lateral, 2 mm posterior and 5 mm caudal to the
midcommissural point (Yoon & Munz, 1999). An incision in the scalp is then made
according to the desired trajectory of the lead and a burr hole is drilled. The planned track
is used for electrophysiological exploration using multiple microelectrodes; participants
of the current thesis usually had five microelectrodes initially inserted for exploration.
Typical firing patterns obtained from the microelectrode recording (MER) is used for
STN localization; asymmetrical spikes at high frequency with bursting patterns are
characteristic features of the STN, whereas symmetrical spikes of large amplitude and
regular activity are characteristic of the SNr (Benabid et al., 2009). Firing patterns along
with patient feedback from stimulation of the microelectrodes (patient is awake with local
anesthesia) is used to determine optimal placement of the chronic/permanent DBS lead.
The IPG is inserted under general anesthesia into a subcutaneous pouch in the
subclavicular area (Benabid et al., 2009).
1.3.1

Reasons for lead misplacement

Appropriate lead placement is a vital component in the success of DBS. However, even
some of the most experienced centers using the most up-to-date technology will have
occurrences of misplaced leads (Ellis et al., 2008). Current pre-operative targeting is
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performed using T2-weighted MRI images whose quality can be compromised enough to
affect visualization of the STN. 7 Tesla (T) MRI, which uses a stronger magnet than the
more common 1.5 T or 3 T MRI, offers higher contrast-to-noise T2-weighted images, but
its current clinical applicability is limited (Fasano & Lozano, 2015). T2-weighted images
in general contain substantial blooming artifacts that cause distortion and prevent the
precise localization of the STN (Fasano & Lozano, 2015). Even if pre-operative planning
is adequate to continue, complications and minor mishaps during the actual surgical
procedure can contribute to lead misplacement. If the frame is misaligned or shifts during
surgery, the lead may deviate to an unintended target (Ellis et al., 2008). As discussed
above, intraoperative MER is used for verification of lead localization; however, errors
due to poor technique or interpretation of MER data can jeopardize accuracy. Brain shifts
may also occur at any time in the surgical process, including preoperative imaging,
microelectrode recording, lead placement, or when a cerebrospinal fluid leak is detected
(Ellis et al., 2008). Additionally, lead deflection is possible due to changes in tissue
density, the angle of approach, or collision with the burr hole or the capping device
(which fastens the permanent lead into place) (Ellis et al., 2008). Given the numerous
reasons for lead misplacement, current steering—to an extent—allows stimulation to be
directed toward the target region. As discussed next, the target region for each symptom
may differ due to differences in pathology.
1.4

Pathophysiology of bradykinesia

The term bradykinesia covers a range of problems in the control of movement; in all
cases, the principal deficit is that movements are slow (Berardelli, 2001). Bradykinesia is
often used synonymously with the terms akinesia and hypokinesia. Specifically,
bradykinesia refers to the slowness of a performed movement whereas akinesia refers to
poverty in spontaneous movement such as in facial expression, or associated movement
such as arm swing during walking (Berardelli, 2001). Hypokinesia refers to movements
that are smaller than desired, especially with regards to repetitive movements. In addition
to whole-body slowness, bradykinesia also includes impairments in fine motor control,
which is demonstrated in PD patients during rapid alternating movements of fingers,
hands, or feet as a progressive reduction of speed and motion amplitude (Magrinelli et al.,
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2016). Although secondary factors such as muscle weakness, tremor and rigidity may
contribute to bradykinesia, primary bradykinesia is potentially due to slowness in
formulating the instructions to move (i.e. programming) or to slowness in executing these
instructions (Berardelli, 2001). Based on studies that reflect motor execution as well as
programming, bradykinesia seems to result primarily from the underscaling of movement
commands in internally generated movements (i.e. in the absence of external cues); this
leads to insufficient recruitment of muscle force during the initiation of movement
(Berardelli, 2001). This has led to the suggestion that bradykinesia is a problem of scaling
motor output appropriately to the task, rather than to any intrinsic limitation in motor
execution (Berardelli, 2001). Deficits in movement preparation in PD patients have been
supported by slower reaction times and slower increase in premovement cortical
excitability, which suggest abnormal retrieval of stored motor commands (Magrinelli et
al., 2016).
The pathophysiology of bradykinesia is not completely understood; however, among the
cardinal motor symptoms of PD, it fits better with the classical model of basal ganglia
function which points at the prevalence of the indirect pathway over the direct one. The
details of this model are outlined in section 1.1.1 and visually presented in Figure 1. The
prevalence of the indirect pathway in this model is used to explain the pathophysiological
hallmark of PD hypokinetic symptoms as resulting from increased neuronal firing in the
GPi and SNr, leading to excessive inhibition of thalamocortical and brainstem motor
systems and causing interference with the speed of movement onset and execution
(Magrinelli et al., 2016). Furthermore, according to this model bradykinesia may result
from the failure of basal ganglia output to reinforce cortical mechanisms responsible for
the preparation or execution of movement (Magrinelli et al., 2016). The idea that beta
synchrony in LFP recordings is implicated in bradykinesia was alluded to in section
1.2.3, which also discussed the finding that DBS was able to suppress the excessive
synchronization. To add to this, premovement electroencephalogram (EEG) beta
desynchronization is reduced in PD patients and this abnormality is partially normalized
by dopaminergic stimulation (Magrinelli et al., 2016). In addition to suppression by DBS,
there is also evidence for beta band synchrony suppression by levodopa, that was
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similarly demonstrated to correlate with improvement in bradykinesia and rigidity, but
not tremor (Magrinelli et al., 2016).
1.5

Pathophysiology of rigidity

Rigidity is characterized by increased muscle tone at rest, increased tension during
passive movement and increased resistance to stretching (Rodriguez-Oroz et al., 2009).
Although both flexor and extensor muscle groups are involved, flexor muscles of the
limbs are more affected in the early stages of the disease (Rodriguez-Oroz et al., 2009).
Rigidity may be enhanced by voluntary movement of other body parts, and increased
resistance is more noticeable when the examined joint is stretched slowly (Magrinelli et
al., 2016).
The pathogenesis of PD rigidity has been hypothesized to include changes in the passive
mechanical properties of joints, tendons and muscles, the enhancement of stretch-evoked
reflexes, and abnormalities in peripheral sensory inputs that can influence the response to
muscle stretch (Magrinelli et al., 2016). The way these changes are associated with
dopamine deficiency, or basal ganglia output as depicted by the classical model, remains
unclear (Magrinelli et al., 2016). The classical model predicts that increased neuronal
activity in the GPi/STN and the resulting inhibition of thalamocortical projections should
result in decreased muscle activation and reduced response to stretching; however, the
opposite is observed with rigidity (Baradaran et al., 2013). Despite the ambiguity,
surgical interventions focusing on the basal ganglia and motor thalamus has a proven
anti-rigidity effect, indicating a role of the motor circuit in the pathogenesis of rigidity
(Rodriguez-Oroz et al., 2009).
Although the pathogenesis of rigidity remains more elusive than other PD cardinal
symptoms, evidence points to a stronger link to bradykinesia than to hyperkinetic
symptoms. As discussed above, excessive beta synchronization in LFP recordings relates
only to the bradykinetic-rigid state that is reversed by dopaminergic therapy (Eusebio &
Brown, 2009). In addition, a longitudinal study looking at the progression of
parkinsonian signs found that bradykinesia and rigidity worsened at similar rates in a
cohort of 237 PD patients, whereas tremor did not (Louis, Tang, & Cote, 1999).
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Suppression of bradykinesia and rigidity also requires lower dosages of levodopa than
tremor (Nonnekes, Timmer, Vries, & Rascol, 2016). There is also evidence to show that
when stimulating the STN during DBS, dorsal/superior spread of current reaching the
internal capsule, thalamus and zona incerta causes improvement in hyperkinetic
symptoms including tremor and dyskinesia, but not hypokinetic symptoms (Wagle
Shukla et al., 2017). Taken together, these conclusions point toward a relationship
between rigidity and bradykinesia management that is separate from tremor.
1.6

Pathophysiology of PD tremor

Tremor, one of the cardinal motor symptoms of PD, is defined as a rhythmic, involuntary,
oscillating movement of one or more body parts (Helmich & Dirkx, 2017). Unlike other
motor symptoms, tremor severity does not correlate with the degree of striatal dopamine
depletion and therefore, tremor response to dopaminergic medication is subpar when
compared to bradykinesia and rigidity (Helmich & Dirkx, 2017). Tremor also has many
types – the classical PD tremor occurs at rest with a frequency of 4 to 6 Hz (Helmich,
Toni, Deuschl, & Bloem, 2013). Many PD patients also have action tremor produced by
voluntary contraction of muscle, and includes postural, isometric, and kinetic tremor
(Helmich et al., 2013). In 34-60% of PD patients, action tremor can be classified as
reemergent resting tremor (Helmich et al., 2013). Reemergent tremor occurs after a delay
of two or more seconds after the limb affected by resting tremor assumes a new posture;
it occurs at the same frequency as resting tremor and it responds to levodopa (Helmich et
al., 2013). Action tremor that is not reemergent tremor occurs at a higher frequency,
between 6 and 15 Hz, and it does not respond to levodopa (Helmich et al., 2013). It is
possible that reemergent tremor and resting tremor in PD are caused by the same
mechanisms, although this finding has not been previously tested (Helmich et al., 2013).
One finding supporting this view is that in many PD patients, voluntary actions suppress
resting tremor, but does not completely interrupt it (Helmich et al., 2013).
There is a consensus towards central, rather than peripheral, mechanisms being
responsible for parkinsonian tremor (Helmich & Dirkx, 2017). This is supported by the
fact that high-frequency DBS of both the basal ganglia and the thalamus is effective in
treating tremor. Studies using intraoperative recordings have found neural oscillations in
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the basal ganglia and the ventral intermediate nucleus of the thalamus (Vim) with the
same frequency as tremor (Helmich & Dirkx, 2017). An important finding is that pallidal
neurons are only transiently and inconsistently coherent with tremor, whereas neurons of
the Vim are highly synchronous; this suggests that the thalamus contributes more to the
driving force behind tremor (Helmich & Dirkx, 2017). One of the first hypotheses
regarding the pathophysiology of tremor was the thalamic pacemaker theory, which states
that hyperpolarized cells in the thalamus act as the tremor pacemaker (Helmich & Dirkx,
2017). The basis for this hypothesis lies in in vitro studies showing that slightly
depolarized thalamic cells oscillate at 10 Hz, whereas hyperpolarized cells oscillate at 6
Hz. These two frequencies coincide with the frequency of physiological tremor and PD
tremor, respectively (Helmich, Hallett, Deuschl, Toni, & Bloem, 2012). In the animal
model, the 6 Hz oscillatory mode is associated with low threshold calcium spikes, which
often follow membrane hyperpolarization. However, this pattern was not observed in the
thalamus of tremor-dominant PD patients (Helmich et al., 2012). Other theories argue
that the tremor pacemaker resides within the basal ganglia, but the theories remain
incomplete due to strong clinical evidence showing the efficacy of Vim-DBS in treating
tremor. More recent studies have been used to construct a model that integrates the role
of both the basal ganglia and the cerebellothalamic circuits in tremor. The dimmer-switch
model of parkinsonian resting tremor introduces the idea of dopaminergic cell death in
the retrorubral field, located dorsally and caudally to the SNc.
Although loss of neurons in the SNc has become the pathological hallmark of PD,
tremor-dominant patients have milder degeneration of the SNc and instead, more
extensive dopaminergic cell loss in the retrorubral area (RRA) of the midbrain (Helmich
& Dirkx, 2017). The exact role of the RRA in the pathogenesis of PD tremor remains
elusive. However, there is evidence to show that resting tremor may result from pallidal
dopamine depletion, resulting from the loss of dopaminergic projections from the RRA to
the pallidum (Helmich, Janssen, Oyen, Bloem, & Toni, 2011). This pallidal dysfunction
leads to pathological activity in the striato-pallidal circuit, which triggers activity in the
cerebellothalamocortical circuit through the primary motor cortex to produce tremor
(Helmich et al., 2011). The dimmer-switch model (Figure 4; Helmich, Hallett, Deuschl,
Toni, & Bloem, 2012) attempts to explain the interaction between the basal ganglia and
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the cerebellothalamocortical circuit in the generation and maintenance of resting tremor.
Rick Helmich and colleagues used concurrent electromyography (EMG) and functional
magnetic resonance imaging (fMRI) to show that the basal ganglia operates analogous to
a light switch that ‘turns on’ tremor, and the cerebellothalamocortical circuit operates
analogous to a light dimmer that modulates tremor amplitude (Helmich et al., 2012).

© Oxford University Press. Used with permission.

Figure 4: Dimmer-switch model of PD resting tremor
Dopaminergic cell death in the retrorubral area in tremor-dominant PD causes dopamine
depletion in the pallidum (in red). This leads to a pathological signal that triggers the
cerebellothalamocortical circuit (in blue) through the primary motor cortex. Therefore,
the striato-pallidal circuit causes the onset of tremor (analogous to a light switch) while
the cerebellothalamocortical circuit produces the tremor and controls its amplitude
(analogous to a light dimmer). VLp: ventral posterolateral nucleus of the thalamus.
1.7

Rationale and hypothesis

As pointed out in Figure 2, the target region for motor symptom alleviation is ideally the
sensorimotor portion of the STN, located in the dorsolateral region. Due to suboptimal
placement of the DBS lead during surgery, the target can be completely missed, or
stimulation of the target can also include current spread to adjacent regions, leading to
adverse effects discussed above. It has been reported that lead misplacement beyond a 23 mm window may result in inadequate clinical benefit (Ellis et al., 2008). Furthermore,
two referral centers for DBS troubleshooting reported that therapy failure in half of the
evaluated leads was caused by suboptimal positioning (Schüpbach et al., 2017). Even
with a theoretically optimal lead location, the functional target can vary from patient to
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patient due to differences in disease phenotype or anatomical variations of the target.
Current steering is a potential solution to address these issues by steering current to the
optimal region in cases of suboptimal lead position, or steering current away from
stimulating non-motor areas of the target or neighboring tissue which can cause adverse
side effects. Technological advancements have made it possible to create non-spherical
electrical field shapes by fractionating current over two or more active contacts. Different
electrical field shapes can stimulate desired structures to different degrees of symptom
alleviation. Therefore, an optimal electrical field shape would localize current to the
desired structure and avoid unintended stimulation of neighboring anatomical structures
for optimal symptom improvement. Thus, it was hypothesized that the way the electrical
field is shaped affects a patient’s upper limb symptom alleviation.
The present literature on current steering (section 1.2.5.1) all contribute to the
advancement of a more individualized form of DBS therapy. Although the first two
studies employed the fractionation of current over two or more contacts (Barbe et al.,
2014; Timmermann et al., 2015), the method used to figure out which setting each patient
was programmed with was a case-by-case scenario; the programming clinician adjusted
stimulation settings continually until optimal clinical effects were observed. With the
VANTAGE study (Timmermann et al., 2015), the reader is unaware of the impact that a
certain current steering setting had across all patients or if one setting happened to benefit
multiple patients optimally. The current thesis provides a more systemic approach that
looks at the effects of current amplitude and a set of current steering settings across all
patients. Detail about the current steering programs was also not revealed in the literature;
the number of contacts involved, and the percentage of current received by each contact
in the stimulation programs was not disclosed. In addition, information about the
response of each type of motor symptom to current steering was lacking; although there
was a reduction in the overall UPDRS motor score from baseline, it is unclear as to what
extent each individual symptom was improved. The current thesis assesses the response
of specific motor symptoms to test how one type of current configuration impacts
different symptoms in the same limb.
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The goal of the current thesis was to explore the effectiveness of current steering as it
relates to appendicular motor symptoms of the upper limbs. These appendicular
symptoms include rest tremor, postural tremor, bradykinesia and rigidity. This study
tested 16 different current fractionation settings; four of these settings solely employ
monopolar stimulation whereas the remaining 12 employ current steering either
unilaterally or bilaterally. As touched upon earlier, the current field created by DBS
systems that allow for current steering is not limited to the relatively spherical electrical
field created by monopolar stimulation. Current steering can be achieved on a horizontal
plane—with directional lead technology—and a vertical plane. Directional leads contain
contacts that are split into three segments such that fractionation of current can be
achieved in horizontal directions. The DBS system used in this study solely explored
current steering in the vertical plane, as demonstrated by Figure 3.
1.7.1

Summary of objectives

Given the variations in lead position, symptom phenotype, and anatomical factors across
patients, the benefits of current steering and/or monopolar stimulation will differ among
patients. For this reason, the first objective tests the effectiveness of current steering
settings in comparison to the monopolar settings for optimal symptom alleviation. The
first objective is as follows:
1) Determine the optimal current fractionation setting and amplitude for each
patient’s upper limb symptom alleviation
The second objective tests if there is a difference in target between the optimal alleviation
of hyperkinetic symptoms and hypokinetic symptoms in the same patient. As discussed,
the classical model of basal ganglia function (Figure 1) and the prevalence of the indirect
pathway over the direct one is the pathophysiological hallmark of PD hypokinetic
symptoms. The model’s prediction of increased STN activity is a plausible reason to
target and inhibit the nucleus with DBS, possibly limiting the excessive inhibition of
thalamocortical systems responsible for normal movement. Hyperkinetic symptoms, on
the other hand, have a different pathophysiology relating to degeneration of the RRA and
involvement of the cerebellothalamocortical circuit (Figure 4). Therefore, the
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management of tremor could possibly involve stimulation of a different region. This
means that hyperkinetic symptoms of a limb will be optimally alleviated by settings that
differ from those that optimally alleviate hypokinetic symptoms. The second objective is:
2) Compare optimal alleviation between hyperkinetic symptoms, rest and postural
tremor, and hypokinetic symptoms, rigidity and bradykinesia, in the same limb
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Chapter 2
2

Methods

This section outlines the methods used for the current study. Participants underwent
bilateral implantation in the STN of a constant-current DBS system capable of current
steering. The current steering investigation lasted approximately four weeks for each
patient in which a set of clinical tasks was performed after each setting change. Study
assessment tools included the UPDRS-III examination as well as motion capture
technology that was used to quantify bradykinesia, postural tremor, rest tremor, and
rigidity of the upper limbs.
2.1

Study participants

Seven PD patients who underwent bilateral STN-DBS were included in this study
analysis; Table 1 outlines the participant demographics. This study was approved by the
Human Research Ethics Board at Western University (REB #108453). The following lists
the inclusion criteria for candidates of the study: (1) idiopathic PD with a 30%
improvement in symptom response to levodopa treatment, assessed by the UPDRS, (2) II
or IV Hoehn-Yahr stage, (3) disabling motor fluctuations with off periods and dyskinesia
during on phases, (4) assessed for eligibility for the DBS procedure, (5) able to give
informed consent, (6) able to visit the clinic for assessment, (7) no dementia or
psychiatric abnormalities on neuropsychological testing. The following lists the exclusion
criteria for candidates: (1) previous brain surgery or cardiac pacemaker, (2) moderately
severe parkinsonism in the context of unstable pharmacological treatment, (3) dementia
as assessed by the Diagnostic and Statistical Manual of Mental Disorders (DSM) V
criteria, (4) severe psychiatric symptoms such as hallucinations and depression, (5) bad
general health, (6) lack of compliance at follow-up visits. All patients in this study had
implantation of the constant-current, multiple-source Vercise DBS System by Boston
Scientific; however, the type of lead implanted (non-directional vs. directional) differed
among patients. Note that although four out of the seven study subjects had a directional
lead implanted, current steering was only investigated in the vertical plane for all
patients.
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Table 1: Participant pool demographics
Participant
ID
BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08
Mean (SD)

Age (yrs)

Sex

55
52
69
63
57
75
61
61.71(±8.10)

M
M
M
F
F
F
F
-

PD Duration
(yrs)
8
12
14
17
12
10
14
12.43(±2.94)

SD: standard deviation of the mean

2.2

Assessment tools

To quantify motor symptoms, a standardized clinical scale and a wearable motion capture
system was used. The UPDRS is the most commonly used scale to follow the course of
PD; part III of this scale is a whole-body motor evaluation that assesses the severity of
certain tasks on a scale of zero to four, zero being normal and four being the most severe
(see Appendix 3). Most literature on the clinical effects of PD use the motor UPDRS
score to quantify symptoms. The problem with this clinical rating scale is that it is
subjective to the rater’s discretion. Although the examining neurologist or researcher
undergoes the same training to administer the UPDRS, the interpretation of the severity
of certain motor symptoms can vary from person to person. In addition to the UPDRS
motor score, the current thesis used objective kinematic measures to track and quantify
body movements similar to motion capture technology used in the entertainment industry.
2.2.1

Motion capture system

Research using sensor systems has gained recent interest in the biomedical field to
monitor human movement. The strengths of this system include its reliability, validity,
flexibility in terms of allowing assessments to be completed outside of clinic, and the
ability to provide large quantities of data for assessment of clinical impact (Gilmore &
Jog, 2017). The major concern with using this type of assessment technique is the ability
to extract relevant features; if not properly analyzed, the sensors can detect small changes
in body movement which may not be characteristic of the symptom being quantified
(Gilmore & Jog, 2017). These systems usually contain 16-19 inertial measurement unit
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(IMU) sensors that are located all over the body and provide information about body
segments. Since the current project was only looking at upper limb movements, the
wearable motion capture system in this study consisted of IMU sensors placed along the
arm (according to Figure 5; Delrobaei, Tran, Gilmore, McIsaac, & Jog, 2016). The
sensors include 3D accelerometers, 3D gyroscopes and 3D magnetometers within each
unit. The relative position and orientation between adjacent sensors enable a fusion
software to identify joint angles. The first study subject (BSC 01) started off using IMU
sensors from the animation company Synertial Ltd. but switched to sensors from the
company Xsens due to better magnetic field detection; the rest of the participants had all
their study visits completed with the Xsens sensors. Data acquisition was performed at 60
Hz sampling rate using Xsens MVN 2018 software. For more details regarding the IMU
hardware and fusion software, please refer to the study by Delrobaei and his colleagues in
2016 which used a similar procedure to assess PD bradykinesia using wearable
technology (Delrobaei et al., 2016).

© Elsevier. Used with permission.

Figure 5: Position of IMU sensors on the upper limbs
Four sensors are placed on each arm, along the hand, forearm, upper arm, and shoulder,
while patients engage in the clinical tasks.
2.3

Clinical tasks and study timeline

To evaluate upper limb bradykinesia, all participants were asked to perform a repetitive
pronation-supination task in a seated position as fast and wide as possible for at least 10
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seconds. The task was performed individually for each arm and repeated for a total of two
trials per arm. Kinematic data was collected using the motion capture system and clinical
scale data was collected using item 3.6 (pronation-supination movements of hands) of the
UPDRS-III examination. This task was validated against the respective UPDRS item
using an IMU-based motion capture system in a study by Delrobaei and colleagues
(Delrobaei et al., 2016). To evaluate upper limb rest and postural tremor, all participants
were asked to perform and repeat the following tasks for a total of two trials:
1) Rest tremor: while sitting, participants rested both of their forearms on the arms of
a chair with their wrists hanging off the edge for at least 20 seconds.
2) Postural tremor: while sitting, participants fully extended their arms forward with
hands pronated at shoulder height level for at least 20 seconds.
Kinematic data was collected using the motion capture system and clinical scale data was
collected using item 3.17 (rest tremor amplitude) and item 3.15 (postural tremor of the
hands) of the UPDRS-III examination. The two tasks were validated against the
respective UDPRS-III items using an IMU-based motion capture system in a second
study by Delrobaei and colleagues (Delrobaei et al., 2018). Rigidity of the upper limbs
was only evaluated using item 3.3 (rigidity) of the UPDRS-III examination.

Figure 6: Study timeline
Pre-assessment occurs within a week before the DBS surgery. Device turn-on occurs at
least four weeks post-operation. The current steering investigation begins at least six
weeks post-operation and lasts for a duration of four weeks.
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As outlined on the timeline in Figure 6, study participants were first assessed within one
week prior to their DBS surgery to determine their response to levodopa medication.
Patients arrived at this visit off any form of levodopa medication for 12+ hours;
kinematic and UPDRS-III data were collected in the medication-off state according to the
clinical tasks mentioned above. Patients were then instructed to take 135% of their usual
levodopa dose and wait approximately 45 minutes for maximal effect of the medication;
kinematic and UPDRS-III data were collected in the medication-on state. At least four
weeks after their DBS surgery, device turn-on occurs. During this visit, a standard
monopolar review of the bottom (ventral) four contacts on the right and left leads was
performed by stimulating each contact individually and increasing current amplitude in
increments of 0.5 mA. An efficacy threshold (minimum amplitude at which improvement
in symptoms occur) and adverse effect threshold (amplitude at which the patient begins
to experience side effects) were used to determine a therapeutic window of current for
each contact. The best contact is one with both a large therapeutic window, and one that
requires the least amount of current to produce symptom benefit. The best and next best
contact was determined for each patient for current fractionation to occur. Most patients
went home from their device turn-on visit on a monopolar stimulation at a minimal level
of current (~0.5 mA), with the best contact that was identified on each side of the brain.
All patients were programmed with a frequency of 130 Hz for the entire duration of the
study and all patients were programmed with a pulse width of 60 µs, except BSC 01 who
was programmed with 90 µs. The choice for stimulation frequency and pulse width as
130 Hz and 60 µs was based on majority of literature showing these values to be
clinically effective.
At least two weeks after device turn-on, or six weeks post-operation, the month long
current steering investigation began. Prior to the investigation, all patients except for the
first (BSC 01) underwent a multipolar review of the contacts to confirm that the secondbest contact was still the most effective when paired with the best contact. The current
steering investigation happened over four consecutive weeks for all patients except for
BSC 08, who had a week gap in the middle of the testing period. Each week consisted of
four consecutive visits to the lab; 16 settings were explored in one week with four
settings tested each day. The 16 different current fractionations are listed in Table 2. The
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settings were randomized across patients such that each patient did not receive the same
order of settings within the week. The same set of 16 settings was repeated in the same
order for each patient in the following weeks at increasing amplitudes. During the first of
the four weeks, the amplitude was set at 20% of the patient’s therapeutic window (TW)
according to the following equation:
𝑊𝑒𝑒𝑘 #1 𝐴𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 = 𝐿𝑜𝑤𝑒𝑟 𝑙𝑖𝑚𝑖𝑡 𝑜𝑓 𝑇𝑊 + (0.20 𝑥 𝑇𝑊)

(1)

The same method was used to calculate the amplitude for week #2, week #3, and week #4
at 40%, 60%, and 80% of each patient’s therapeutic window, respectively. Note that for
BSC 08 only, the amplitude was set at 60% of the therapeutic window at week #4 instead
of week #3, and 80% of the therapeutic window at week #3 instead of week #4. However,
for simplification, ‘Week 3’ indicated on Tables 6-13 signifies a testing amplitude that
was 60% of the therapeutic window for all patients, and likewise ‘Week 4’ signifies a
testing amplitude that was 80% of the therapeutic window for all patients. The following
settings were not tested at the respective week’s amplitude for the mentioned participants:
setting 13 at week 4 amplitude for BSC 03, setting 13 at week 3 and 4 amplitude for BSC
07. The reason for not testing was due to unmanageable dyskinesia that caused
discomfort to both participants and interfered with testing equipment.
Patients arrived each day off any levodopa medication for 12+ hours. After each current
steering setting was programmed, a 25-minute wait period was given to allow for the
stimulation to take effect. Kinematic and UPDRS-III data was collected after each setting
change while the patient performed the clinical tasks mentioned above. At the end of
each day following the four setting changes, the patient went home with a baseline
setting. During the first week of the current steering investigation, patients went home
with a baseline setting that fractionated current equally between the best and next best
contact (50%-50% split) on the left and right leads, at a minimal amplitude of current. At
the end of the week, patients went home with a setting from the 16 tested settings that
provided the greatest clinical benefit according to a total-body UPDRS-III score, at the
week’s testing amplitude; this became the new baseline setting with which the patients
returned the following week. At the end of the four weeks, patients concluded the study

32

by going home on the setting and corresponding amplitude that was optimal across all
weeks, again according to a total-body UPDRS-III score (Table 5).

Table 2: Current fractionation settings
Setting Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Left STN
A: 100% B: 0%
A: 100% B: 0%
A: 100% B: 0%
A: 100% B: 0%
A: 70% B: 30%
A: 70% B: 30%
A: 70% B: 30%
A: 70% B: 30%
A: 50% B: 50%
A: 50% B: 50%
A: 50% B: 50%
A: 50% B: 50%
A: 0% B: 100%
A: 0% B: 100%
A: 0% B: 100%
A: 0% B: 100%

Right STN
A: 100% B: 0%
A: 70% B: 30%
A: 50% B: 50%
A: 0% B: 100%
A: 100% B: 0%
A: 70% B: 30%
A: 50% B: 50%
A: 0% B: 100%
A: 100% B: 0%
A: 70% B: 30%
A: 50% B: 50%
A: 0% B: 100%
A: 100% B: 0%
A: 70% B: 30%
A: 50% B: 50%
A: 0% B: 100%

STN: subthalamic nucleus; A and B represent the best two contacts at the left and right STN; setting numbers in red
indicate settings where current steering occurs either unilaterally or bilaterally; the remaining four settings employ
bilateral monopolar stimulation.

2.3.1

Feature extraction

Joint angles were obtained from the four IMUs placed along the wrist, elbow, and
shoulder of each arm (Figure 5). For bradykinesia assessment, the following features
were extracted from each joint angle to analyze upper limb motion: standard deviation of
the signal (STD), angular velocity (Vel), and variability in terms of time (Time_Var) and
amplitude (Amp_Var). Joint angle signals were extracted and analyzed for three arm
joints to examine wrist rotation relative to the elbow, elbow rotation relative to the
shoulder, and shoulder rotation relative to the fixed back reference. For more information
regarding the feature extraction process, please refer to section 2.3 of the study published
by Delrobaei and his team (Delrobaei et al., 2016). An improvement in bradykinesia
would show increases in STD and Vel, and decreases in Time_Var and Amp_Var. From
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this, the bradykinesia index (BKI) calculation can be derived to quantify bradykinesia for
the repetitive pronation-supination task:

(1)
The BKI can be calculated individually at each joint involved in generating the arm
rotation such that a BKI for the wrist (BKIWrist), elbow (BKIElbow), and shoulder
(BKIShoulder), is computed. In the referenced study (Delrobaei et al., 2016), a total arm
BKI was calculated according to equation (2) below. However, for the current thesis
BKIShoulder was omitted because shoulder rotation was much slower in the participants
relative to wrist and elbow rotation and thus total arm BKI was not an accurate reflection
of their bradykinetic state. In addition, joint angle signals for the wrist and elbow are
combined; the reason for the combined signal is because the relative position of the
forearm sensor to the hand and upper arm sensors affects the individual joint angle
signals from the wrist and elbow. Therefore, instead of using BKIWrist and BKIElbow that
are calculated using joint angles from the wrist and elbow, respectively, the combined
signal was used to calculate a total forearm BKI (BKIForearm) that better reflects the
patient’s upper limb bradykinetic state (equation (3)).

(2)

(3)
For tremor assessment, the list of measured joint angles for the right and left arm is
displayed in Table 3. A tremor severity score (TSS) was calculated at each joint so tremor
severity could be quantified for the total arm. To calculate this score, signals containing
angular displacements of all arm joints were band-pass filtered from 4 Hz to 20 Hz to
eliminate non-tremor movements. The higher end of the filtering range was set at 20 Hz
because some forms of action tremor fall between frequencies of 6 Hz and 15 Hz. The
root-mean-square (RMS) of each filtered signal associated with each joint was calculated
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as the TSS for that joint. The RMS of all joints associated with each limb’s TSS was
calculated as the TSS for that limb. Therefore, the TSS for each arm is calculated
according to equation (4).
Table 3: List of joint angles for tremor assessment
Body part
Right arm

Segment
Right wrist

Right elbow
Right shoulder

Left arm

Left wrist

Left elbow
Left shoulder

Motion
Flexion/extension
Ulnar/radial
Pronation/supination
Flexion/extension
Pronation/supination
Flexion/extension
Abduction/adduction
Rotation
Flexion/extension
Ulnar/radial
Pronation/supination
Flexion/extension
Pronation/supination
Flexion/extension
Abduction/adduction
Rotation

𝑇𝑆𝑆 = 𝑅𝑀𝑆 [𝐹4−20𝐻𝑧 (𝐽𝑖 )]

(4)

Ji is the ith joint movement; the maximum number of joint movements involved in the
calculation for each arm is eight (see Table 3). F4-20Hz represents signals filtered from 4
Hz to 20 Hz, and RMS represents the root-mean-square of all joints forming the signal.
For more information regarding the TSS calculation, refer to section 2.4 in the study
published by Delrobaei and his colleagues who used the same procedure for monitoring
whole-body tremor using wearable technology (Delrobaei et al., 2018).
2.4

Data analysis

To determine each patient’s weekly optimal setting from kinematic data, raw BKI and
TSS values were normalized to a minimum and maximum. The values used for
normalization were determined using kinematic data from two neurologists who
mimicked the motor performance of a healthy participant when performing the clinical
tasks to obtain a minimum BKI and TSS, and that of a severe PD patient to obtain a
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maximum BKI and TSS. MATLAB R2017b was used to create 3D scatter plots with
bradykinesia values (expressed as a percentage) from each setting plotted on the x-axis,
postural tremor values (expressed as a percentage) plotted on the y-axis, and rest tremor
values (expressed as a percentage) plotted on the z-axis. The 3D graphs also included
kinematic values from each patient’s baseline visit which occurred prior to DBS surgery
in the medication-off, stimulation-off (OFF) state. The Euclidean distance (ED) of each
data point to the center of the graph was calculated according to equation (5); the optimal
setting had the smallest ED to the center (represents the minimum of the normalized
values).
𝐸𝐷 = √(𝑥2 − 𝑥1 )2 + (𝑦2 − 𝑦1 )2 + (𝑧2 − 𝑧1 )2

(5)

A non-parametric Wilcoxon matched-pairs signed rank test was used to compare the ED
of the OFF state of patients with the ED of the optimal setting determined from all four
weeks. Statistical significance was set at p < .05 (two-sided). Statistics were conducted
using GraphPad Prism 7.
To compare UPDRS-III scores across settings for each patient, raw scores from items
3.15 (postural tremor of hands), 3.17 (rest tremor amplitude), 3.3 (rigidity), and 3.6
(pronation-supination movements of hands) were converted to z-scores according to the
following equation:

𝑧=

(𝑥− 𝜇)
𝜎

(6)

x represents the raw item score from 0 to 4, µ represents the mean of the item score for
all patients at each week, σ represents the standard deviation of the mean. Microsoft
Excel 2016 was used to plot the z-scores on radar charts. A chi-squared test was used to
assess the types of settings that made up instances where simultaneous optimal alleviation
of hyperkinetic and hypokinetic symptoms occurred in the same limb, as well as
instances where only optimal alleviation of hyperkinetic or hypokinetic symptoms
occurred in a limb. Degrees of freedom was set at 1 and statistical significance was set at
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p < .05. Statistics were conducted using guidelines outlined in Statistical Methods Sixth
Edition (Cochran & Snedecor, 1974).
2.4.1

Electrode localization

Patients in this study underwent post-operative computed tomography (CT) scans that
showed the final lead location. Pre-operative MRI scans were co-registered to postoperative CT scans using NiftyReg software, and MER data was brought into the same
space to show localization of the DBS lead at the STN. MER electrode coordinates were
extracted from the StealthStation planning machine according to the surgical plan. MER
data of each patient was used to reconstruct the microelectrode tracks on the MRI/CT
fusion and was visualized with 3D Slicer (Appendix 4).
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Chapter 3
3

Results

This chapter presents the results of seven PD participants who underwent bilateral STNDBS and an approximate month-long current steering investigation post-operation.
3.1

Study participants: clinical outcomes

Initially, eight PD participants were recruited; however, BSC 04 was forced to drop out
of the study due to a failed psychological assessment prior to receiving DBS surgery. As
outlined in Table 1 in the Methods section, three males and four females met the
inclusion and exclusion criteria. The mean age of the participants was 61.71 ± 8.10 years
and the mean disease duration was 12.43 ± 2.94 years. As mentioned above, each patient
underwent a contact review prior to the current steering investigation to identify the best
two contacts on each side of the brain, i.e. the optimal stimulation sites. Results from the
contact review as well as the amplitude ranges defining the therapeutic window of each
patient are presented below.

Figure 7: Optimal stimulation sites
Simulation of the left and right lead with the bottom four contacts on each lead (shown as
rings) displayed for each patient; contacts in pink represent the two best contacts on each
lead chosen for current fractionation. Size of the lead and contacts are not to scale. L;
lead implanted in the left subthalamic nucleus; R: lead implanted in the right subthalamic
nucleus.
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Table 4: Lower and upper amplitude limits of the therapeutic window
Participant
ID

Therapeutic Window at Left
STN

Therapeutic Window at Right
STN

BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08
Mean (SD)

Lower Limit
(mA)
2
1
1
0.5
1.5
1.5
1.5
1.29 (±0.49)

Lower Limit
(mA)
0.75
1
1
0.5
1
1.5
1.5
1.04 (±0.37)

Upper Limit
(mA)
6
3.5
4.5
3
3.5
3.4
4
3.99 (±1.01)

Upper Limit
(mA)
6
3
5
3.5
4
5.6
3
4.3 (±1.24)

SD: standard deviation of the mean; STN: subthalamic nucleus; current amplitude values are displayed
in milliamperes(mA); lower limit defined by minimum amplitude at which symptom improvement occurs;
upper limit defined by maximum amplitude patient can withstand before experiencing adverse side
effects.

Recall that at the end of the current steering investigation, patients went home with a
setting that was optimal among the four weeks, as measured by a whole-body UPDRS-III
score. The whole-body UPDRS-III score takes into consideration speech, facial
expression, rest tremor of the head and the upper and lower limbs, postural tremor of the
upper limbs, rigidity of the neck and the upper and lower limbs, bradykinetic state
assessed by finger taps, hand and arm movements and arising from a chair, leg agility,
posture and postural stability, gait and whole-body bradykinesia (Appendix 3). This
setting showed a consistent improvement of whole-body symptoms at each week’s
amplitude. Patients went home at the end of the study with this setting paired with the
amplitude of the week at which the setting caused optimal symptom improvement. Table
5 lists this setting for each patient.
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Table 5: Optimal setting at study conclusion according to whole-body UPDRS score
Participant ID Optimal Setting
14
BSC 01
8
BSC 02
2
BSC 03
4
BSC 05
2
BSC 06
8
BSC 07
10
BSC 08
Setting 4: bilateral monopolar

3.2

Objective #1 results

The first objective was to determine the optimal current fractionation setting and
amplitude for each patient’s upper limb symptom alleviation. To quantify symptoms for
this objective, kinematic data from IMU sensors was used to quantify upper limb rest
tremor, upper limb postural tremor and upper limb bradykinesia while participants were
engaged in the three seated tasks outlined in section 2.4. 3D scatter plots were created to
determine the optimal setting for the three symptoms, defined by the setting having the
smallest Euclidean distance to the center of the graph (refer to section 2.5 for data
analysis method). Figures 8-14 show panels created for each patient that display 3D
graphs for each week.
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Figure 8: 3D graphs of kinematic data for BSC 01
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 01. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
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tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
to 2.8 mA on the left lead and 1.8 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 3.6 mA on the left lead and 2.8 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 4.4 mA on the left lead and 3.9 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 4.8 mA on the left lead and 4.4 mA on
the right lead. Plotted values are normalized percentages.
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Figure 9: 3D graphs of kinematic data for BSC 02
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 02. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set

43

to 1.5 mA on the left lead and 1.4 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 2 mA on the left lead and 1.8 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 2.5 mA on the left lead and 2.2 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 3 mA on the left lead and 2.6 mA on
the right lead. Plotted values are normalized percentages.
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Figure 10: 3D graphs of kinematic data for BSC 03
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 03. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
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to 1.7 mA on the left lead and 1.8 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 2.4 mA on the left lead and 2.6 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 3.1 mA on the left lead and 3.4 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 3.8 mA on the left lead and 4.2 mA on
the right lead. Plotted values are normalized percentages.
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Figure 11: 3D graphs of kinematic data for BSC 05
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 05. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
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to 1 mA on the left lead and 1.1 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 1.5 mA on the left lead and 1.7 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 2 mA on the left lead and 2.3 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 2.5 mA on the left lead and 2.9 mA on
the right lead. Plotted values are normalized percentages.
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Figure 12: 3D graphs of kinematic data for BSC 06
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 06. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
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to 1.9 mA on the left lead and 1.6 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 2.3 mA on the left lead and 2.2 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 2.7 mA on the left lead and 2.8 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 3.1 mA on the left lead and 3.4 mA on
the right lead. Plotted values are normalized percentages.
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Figure 13: 3D graphs of kinematic data for BSC 07
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 07. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
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to 1.9 mA on the left lead and 2.3 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 2.2 mA on the left lead and 3.1 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 2.6 mA on the left lead and 3.9 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 3.0 mA on the left lead and 4.7 mA on
the right lead. Plotted values are normalized percentages.
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Figure 14: 3D graphs of kinematic data for BSC 08
3D visualizations of kinematic parameters measured at baseline (OFF) and during 16
current fractionation settings tested at each week on BSC 08. Bradykinesia (BK) is
represented on the x-axis, postural tremor (PT) is represented on the y-axis, and rest
tremor (RT) is represented on the z-axis. Current amplitude at week 1 (A and B) was set
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to 2 mA on the left lead and 1.8 mA on the right lead. Current amplitude at week 2 (C
and D) was set to 2.5 mA on the left lead and 2.1 mA on the right lead. Current amplitude
at week 3 (E and F) was set to 3.5 mA on the left lead and 2.7 mA on the right lead.
Current amplitude at week 4 (G and H) was set to 3.0 mA on the left lead and 2.4 mA on
the right lead. Plotted values are normalized percentages.

Table 6 summarizes the findings from Figures 8-14 where the optimal setting, for upper
limb alleviation of rest tremor, postural tremor and bradykinesia, of each week for all
patients was found by calculating the Euclidean distance from the data point of each
setting to the center of the 3D graph; the optimal setting had the smallest Euclidean
distance to the center. The settings listed in Table 6 are grouped according to the use of
current steering either unilaterally (settings in green/purple), bilaterally (settings in red),
or the absence of current steering, i.e. a bilateral monopolar stimulation (bolded settings).
Settings in green have current steering occurring at the STN that is contralateral to the
limb being affected (i.e. left STN for right limb, right STN for left limb) whereas settings
in purple have current steering occurring at the STN that is ipsilateral to the affected limb
(i.e. left STN for left limb, right STN for right limb). The highlighted settings for each
patient indicate the optimal setting across all four weeks, at the corresponding week’s
amplitude.
Figure 15 shows the results of a two-tailed Wilcoxon matched-pairs signed rank test
(non-parametric) to determine whether there is a significant difference between the
Euclidean distances of each patient’s OFF data point to the center of the 3D graph and the
Euclidean distances of each patient’s optimal setting (highlighted settings in Table 6) to
the center. Significance was found between the two groups for the left (n = 7, p = 0.0156)
and right (n = 7, p = 0.0313) upper limb.
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Table 6: Optimal settings for upper limb rest tremor, postural tremor and
bradykinesia determined by kinematic data

Week 1
Week 2
Week 3
Week 4

BSC 01 BSC 02 BSC 03 BSC 05 BSC 06 BSC 07 BSC 08
L R L R L R L R L R L R L R
11 11 4 6 1 5 1 12 6 16 11 14 1 1
14 14 2 2 1 4 6 13 13 4 14 15 7 7
8 2 8 1 1 3 4 6
14 16 15 7 12
8 3 3 3 2 2 11 6 6 7 8 12 3 7

L: left upper limb; R: right upper limb; settings in red represent the occurrence of bilateral current steering, bolded
settings are monopolar setting, settings in green employ current steering at the STN contralateral to the limb, settings
in purple employ current steering at the STN ipsilateral to the limb; highlighted settings represent the setting of each
upper limb that was optimal across all weeks. Week 1 settings were optimal at 20% of each patient’s therapeutic
window. Week 2 settings were optimal at 40% of each patient’s therapeutic window. Week 3 settings were optimal at
60% of each patient’s therapeutic window. Week 4 settings were optimal at 80% of each patient’s therapeutic window.

Figure 15: Euclidean distances (EDs) of optimal settings for alleviation of rest
tremor, postural tremor and bradykinesia in the left and right upper limbs of
patients with Parkinson's disease
A statistically significant difference was revealed between the EDs of the OFF group and
the EDs of the optimal settings for the A) left upper limb (n = 7, p = 0.0156*) and B)
right upper limb (n = 7, p = 0.0313*) of patients with Parkinson’s disease. Results are
reported as the mean +/- SD. A two-tailed, Wilcoxon matched-pairs signed rank test was
completed. ED: Euclidean distance.
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3.3

Objective #2 results

To compare the responses of hyperkinetic symptoms and hypokinetic symptoms of the
upper limbs to each current fractionation setting, UPDRS-III subscores were converted to
z-scores and graphed on radar charts (refer to section 2.5 for data analysis method). Items
3.15 (postural tremor of hands) and 3.17 (rest tremor amplitude) defined hyperkinetic
symptoms and items 3.3 (rigidity) and 3.6 (bradykinesia: pronation-supination
movements of hands) defined hypokinetic symptoms (see Appendix 3). Panels of radar
charts for each patient are displayed in Figures 16-22.

Figure 16: Radar charts of UPDRS-III subscores for BSC 01
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 01; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and

56

bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 2.8 mA on the left lead and 1.8 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 3.6 mA on the left lead
and 2.8 mA on the right lead. Current amplitude at week 3 (E and F) was set to 4.4 mA
on the left lead and 3.9 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 4.8 mA on the left lead and 4.4 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.

Figure 17: Radar charts of UPDRS-III subscores for BSC 02
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 02; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
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item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 1.5 mA on the left lead and 1.4 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 2 mA on the left lead
and 1.8 mA on the right lead. Current amplitude at week 3 (E and F) was set to 2.5 mA
on the left lead and 2.2 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 3 mA on the left lead and 2.6 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.

Figure 18: Radar charts of UPDRS-III subscores for BSC 03
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 03; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 1.7 mA on the left lead and 1.8 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 2.4 mA on the left lead

58

and 2.6 mA on the right lead. Current amplitude at week 3 (E and F) was set to 3.1 mA
on the left lead and 3.4 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 3.8 mA on the left lead and 4.2 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.

Figure 19: Radar charts of UPDRS-III subscores for BSC 05
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 05; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 1 mA on the left lead and 1.1 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 1.5 mA on the left lead
and 1.7 mA on the right lead. Current amplitude at week 3 (E and F) was set to 2 mA on
the left lead and 2.3 mA on the right lead. Current amplitude at week 4 (G and H) was set
to 2.5 mA on the left lead and 2.9 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.
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Figure 20: Radar charts of UPDRS-III subscores for BSC 06
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 06; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 1.9 mA on the left lead and 1.6 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 2.3 mA on the left lead
and 2.2 mA on the right lead. Current amplitude at week 3 (E and F) was set to 2.7 mA
on the left lead and 2.8 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 3.1 mA on the left lead and 3.4 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.
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Figure 21: Radar charts of UPDRS-III subscores for BSC 07
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 07; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 1.9 mA on the left lead and 2.3 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 2.2 mA on the left lead
and 3.1 mA on the right lead. Current amplitude at week 3 (E and F) was set to 2.6 mA
on the left lead and 3.9 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 3.0 on the left lead and 4.7 on the right lead. UPDRS: Unified Parkinson’s Disease
Rating Scale.
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Figure 22: Radar charts of UPDRS-III subscores for BSC 08
Visual representations showing the effect of 16 current fractionation settings (labeled
around the circumference of each radar chart) on upper limb symptoms. A-H show results
at each week for the left and right upper limb of BSC 08; the left chart displays rest
tremor (RT) and postural tremor (PT) and the right chart displays rigidity (Rid) and
bradykinesia (BK). The left charts in A-H all display hyperkinetic (RT and PT)
symptoms and the right charts in A-H all display hypokinetic (Rid and BK) symptoms.
Graphed values are z-scores calculated from raw scores for UPDRS item 3.15, item 3.17,
item 3.3, and item 3.6, representing postural tremor, rest tremor, rigidity, and
bradykinesia, respectively. Distance from the center represents symptom severity.
Current amplitude at week 1 (A and B) was set to 2 mA on the left lead and 1.8 mA on
the right lead. Current amplitude at week 2 (C and D) was set to 2.5 mA on the left lead
and 2.1 mA on the right lead. Current amplitude at week 3 (E and F) was set to 3.5 mA
on the left lead and 2.7 mA on the right lead. Current amplitude at week 4 (G and H) was
set to 3 mA on the left lead and 2.4 mA on the right lead. UPDRS: Unified Parkinson’s
Disease Rating Scale.
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The radar charts were used to determine optimal settings for hyperkinetic symptoms and
hypokinetic symptoms according to the UPDRS-III subscores. For example, looking at
display A)I. in Figure 22 showing the hyperkinetic radar chart of rest tremor (blue
connected line) and postural tremor (orange connected line), setting 15 is the only setting
that has the coordinate for rest tremor at the center of the graph; therefore, setting 15,
when compared to the rest of the settings, is optimal for hyperkinetic symptom alleviation
in the left upper limb of BSC 08 at week 1. A summary of these optimal settings for
hyperkinetic and hypokinetic symptoms for each patient at each week is displayed in
Tables 7-10. The tables also highlight in red which settings were optimal in each patient’s
upper limbs for alleviation of both hyperkinetic and hypokinetic symptoms. Put another
way, the settings in red are optimal for hyperkinetic and hypokinetic symptom alleviation
in the same limb.
Table 7: Week 1 optimal settings determined by UPDRS-III subscores
Hyperkinetic
BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S2, S7, S8, S9, S10, S11, S15, S16
S7
S2, S4, S7, S10, S11, S13, S14, S16
S1, S2, S4, S5, S6, S7, S8, S9, S10, S12, S15, S16
S2, S5, S7, S8, S9, S11, S12, S13, S15, S16
S1, S4, S5, S6, S8, S9, S11, S12, S14, S16
S15

BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S3, S4, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16
S1
S5
S7
S4, S13, S16
S8
S1, S2, S8, S9

R
S2, S7
S5
S15
S1, S2, S3, S4, S6, S7, S8, S9, S10, S11, S12, S14, S15, S16
S1, S2, S4, S7, S13, S14, S16
S1, S2, S3, S4, S5, S6, S7, S8, S9, S11, S12, S13, S14, S15, S16
S2
Hypokinetic
R
S3, S4, S10, S14, S15, S16
S7, S8, S9
S2
S15
S9, S10
S4, S5, S6, S7, S8, S10, S15
S1, S2, S15

UPDRS: Unified Parkinson’s Disease Rating Scale; L: left upper limb; R: right upper limb; optimal settings for
hyperkinetic symptoms (top) and hypokinetic symptoms (bottom) determined by UPDRS item scores for the left and
right upper limb of all patients at week 1; settings in red indicate optimal settings for both hyperkinetic and hypokinetic
symptoms, in the same patient for the same limb.
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Table 8: Week 2 optimal settings determined by UPDRS-III subscores
Hyperkinetic
BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S3, S7, S8, S9, S10, S12
S1, S2, S3, S4, S7, S8, S11, S12, S13, S14, S15
S12
S1, S2, S3, S4, S6, S7, S8, S11, S13, S14, S15, S16
S1, S2, S4, S5, S6, S7, S8, S11, S12, S13, S14, S16
S1, S4, S5, S8, S10, S11, S12, S16
S1, S5, S11, S16

BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S2, S5, S6, S7, S9, S10, S11, S12, S16
S2, S15
S1, S5
S4, S13
S2, S7, S8, S12
S2, S3, S5, S6, S8, S10, S12, S14, S16
S7, S9, S10, S13

R
S1, S2, S5, S7, S12, S14, S16
S10, S13
S1, S3, S11, S13
S4
S1, S2, S5, S6, S7, S8, S9, S11, S12, S13, S14, S16
S1, S2, S3, S4, S5, S6, S8, S9, S10, S12, S16
S13
Hypokinetic
R
S1, S2, S3, S6, S7, S8, S9, S10, S13, S14
S2
S3, S4
S15
S1, S2, S3, S10, S11, S14
S7, S8, S9, S13, S16
S10

UPDRS: Unified Parkinson’s Disease Rating Scale; L: left upper limb; R: right upper limb; optimal settings for
hyperkinetic symptoms (top) and hypokinetic symptoms (bottom) determined by UPDRS item scores for the left and
right upper limb of all patients at week 2; settings in red indicate optimal settings for both hyperkinetic and hypokinetic
symptoms, in the same patient for the same limb.

Table 9: Week 3 optimal settings determined by UPDRS-III subscores
Hyperkinetic
BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S3
S3, S8
S2, S3, S4, S5, S6, S7, S8, S10, S11, S12
S1, S2, S3, S4, S6, S8, S10, S13, S16
S2
S2, S3, S4, S6, S8, S10, S12, S15, S16
S2, S6, S12, S13

BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S8, S11, S15, S16
S3, S8, S15
S6
S2, S3, S4, S5, S8, S13, S15
S4, S8
S1, S4, S8, S11, S12, S16
S3, S4, S5, S6, S8, S12, S16

R
S2
S1, S3, S6, S8
S2, S3, S4, S5, S6, S8, S9, S11, S13, S14, S16
S4, S13
S2, S6
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S12, S14, S16
S1, S3, S4, S6, S13, S16
Hypokinetic
R
S11
S2, S3, S5, S6, S8, S10, S13, S15
S7, S9
S2, S13
S6, S13, S14
S2, S3, S4, S11, S14, S16
S8

UPDRS: Unified Parkinson’s Disease Rating Scale; L: left upper limb; R: right upper limb; optimal settings for
hyperkinetic symptoms (top) and hypokinetic symptoms (bottom) determined by UPDRS item scores for the left and
right upper limb of all patients at week 3; settings in red indicate optimal settings for both hyperkinetic and hypokinetic
symptoms, in the same patient for the same limb.
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Table 10: Week 4 optimal settings determined by UPDRS-III subscores
Hyperkinetic
BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S1, S2, S4, S6, S7, S8, S10, S11, S12, S13, S15, S16
S4
S1, S7, S11, S15
S2, S4, S5, S6, S8, S9, S11, S13, S14, S15
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S14, S15, S16
S1, S2, S3, S4, S7, S8, S9, S10, S11, S12, S14, S15, S16
S1

BSC 01
BSC 02
BSC 03
BSC 05
BSC 06
BSC 07
BSC 08

L
S3, S4, S7, S13, S16
S3
S5
S5, S7, S8, S10, S11, S12, S16
S4, S5, S6, S11, S15, S16
S2, S4, S5, S7, S8, S9, S10, S11
S1, S4, S5, S10, S11, S12, S15, S16

R
S1, S3, S4, S5, S9, S10, S12
S3, S4
S1, S2, S3, S7, S8, S9, S10, S12, S14, S15, S16
S4
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16
S1, S2, S3, S5, S6, S7, S8, S9, S10, S11, S12, S14, S15, S16
S1, S7, S10
Hypokinetic
R
S2, S3
S8, S9, S10
S2
S1, S3, S4, S5, S6, S7, S8, S10, S11, S12, S14, S16
S5, S8, S10
S2, S4, S7, S8, S9, S11, S15
S1, S15

UPDRS: Unified Parkinson’s Disease Rating Scale; L: left upper limb; R: right upper limb; optimal settings for
hyperkinetic symptoms (top) and hypokinetic symptoms (bottom) determined by UPDRS item scores for the left and
right upper limb of all patients at week 4; settings in red indicate optimal settings for both hyperkinetic and hypokinetic
symptoms, in the same patient for the same limb.

A further analysis was done to determine the types of settings that occurred in instances,
involving all patients, where there was simultaneous optimal alleviation of hyperkinetic
and hypokinetic symptoms in the same limb (settings in red in Tables 7-10). Table 11
shows this breakdown as the proportion of instances at each week, involving all patients,
that contained settings employing bilateral current steering (group 1), bilateral monopolar
stimulation (group 2), current steering at the contralateral STN (group 3), and current
steering at the ipsilateral STN (group 4). Recall that current steering at the contralateral
STN refers to settings that have a current fractionation other than a 0%-100% split at the
STN that is contralateral to the limb being tested. Likewise, current steering at the
ipsilateral STN refers to settings that have a current fractionation other than a 0%-100%
split at the STN that is ipsilateral to the limb being tested A chi-square assessment of the
values in Table 11 with degrees of freedom of 1 (df = 1) and alpha level of significance
of 0.05 returned statistical significance (p < 0.05) between group 3 and group 4 when the
number of occurrences in each group were totaled for all four weeks.
Table 12 breaks down the types of settings that made up instances, involving all patients,
where only optimal hyperkinetic symptom alleviation in a limb was achieved, using the
same four groups to categorize the settings. A chi-square assessment of the values in
Table 12 returned statistical significance between group 2 and group 3 (df = 1, p < 0.05)
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at week 2 for the left upper limb and between group 2 and group 4 (df = 1, p < 0.05) at
week 2 for the right upper limb.
Table 13 breaks down the types of settings that made up instances, involving all patients,
where only optimal hypokinetic symptom alleviation in a limb was achieved. A chisquare assessment of the values in Table 13 returned no statistical significance between
any two groups at each week (df = 1, p > 0.05).

Table 11: Chi-square assessment of instances involving settings that optimally
alleviate hyperkinetic and hypokinetic symptoms in the same limb

Week 1 - L
Week 1 - R

Group 1 - Group 2 Group 3 Total Instances Bilateral Monopolar Contralateral
11
4
3
1
8
2
1
2

Group 4 Ipsilateral
3
3

Week 2 - L

17

4

3

3

7

Week 2 - R

12

2

3

2

5

Week 3 - L
Week 3 - R
Week 4 - L

14
11
21

2
2
7

4
3
7

3
2
2

5
4
5

Week 4 - R

13

3

2

4

Total

107

26

26

4
a

19

36a

STN: Subthalamic nucleus; L: left upper limb; R: right upper limb. Group 1 contains instances where the setting
employed bilateral current steering. Group 2 contains instances where the setting employed bilateral monopolar
stimulation. Group 3 contains instances where the setting employed current steering at the STN contralateral to the
testing limb. Group 4 contains instances where the setting employed current steering at the STN ipsilateral to the
testing limb. A chi-square test was performed using degrees of freedom (df) of 1 and alpha of 0.05. There was a
statistically significant difference between the total number of occurrences in group 3 (current steering at the STN
contralateral to the limb) and the total number of occurrences in group 4 (current steering at the STN ipsilateral to the
limb) across all weeks (df = 1, p < 0.05a).

66

Table 12: Chi-square assessment of instances involving settings that optimally
alleviate only hyperkinetic symptoms in a limb

Week 1 - L
Week 1 - R

Total Instances
39
33

Group 1 Bilateral
10
7

Week 2 - L

20

9

13a

4a

11

6
7
6
8
10
63

a

8
8
6
12
10
63

2a
3
6
7
10
54

Week 2 - R
Week 3 - L
Week 3 - R
Week 4 - L
Week 4 - R
Total

14
22
28
35
41
232

Group 2 Group 3 Monopolar Contralateral
9
9
10
10
10
4
10
8
11
52

Group 4 Ipsilateral
11
6

STN: Subthalamic nucleus; L: left upper limb; R: right upper limb. A chi-square test was performed using degrees of
freedom (df) of 1 and alpha of 0.05. Group 1 contains instances where the setting employed bilateral current steering.
Group 2 contains instances where the setting employed bilateral monopolar stimulation. Group 3 contains instances
where the setting employed current steering at the STN contralateral to the testing limb. Group 4 contains instances
where the setting employed current steering at the STN ipsilateral to the testing limb. There was a statistically
significant difference between group 2 (bilateral monopolar stimulation) and group 3 (current steering at the STN
contralateral to the limb) at week 2 for the left upper limb (df = 1, p < 0.05a) and between group 2 (bilateral
monopolar stimulation) and group 4 (current steering at the STN ipsilateral to the limb) at week 2 for the right upper
limb (df = 1, p < 0.05a).

Table 13: Chi-square assessment of instances involving settings that optimally
alleviate only hypokinetic symptoms in a limb

Week 1 - L
Week 1 - R
Week 2 - L
Week 2 - R
Week 3 - L
Week 3 - R
Week 4 - L
Week 4 - R
Total

Total Instances
13
15
15
14
18
12
13
17
117

Group 1 Bilateral
1
4
5
5
4
4
2
5
30

Group 2 Group 3 Group 4 Monopolar Contralateral Ipsilateral
5
3
4
3
4
4
3
4
3
3
3
3
5
4
5
2
1
5
3
3
5
3
6
3
27
28
32

STN: Subthalamic nucleus; L: left upper limb; R: right upper limb. Group 1 contains instances where the setting
employed bilateral current steering. Group 2 contains instances where the setting employed bilateral monopolar
stimulation. Group 3 contains instances where the setting employed current steering at the STN contralateral to the
testing limb. Group 4 contains instances where the setting employed current steering at the STN ipsilateral to the
testing limb. A chi-square test was performed using degrees of freedom (df) of 1 and alpha of 0.05. There was no
statistical significant difference between any two values at each week (df = 1, p > 0.05).
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Chapter 4
4

Discussion

The current study aimed at determining the effectiveness of current steering in the
alleviation of appendicular motor symptoms of the upper limbs. It was hypothesized that
the way the electrical field was shaped will affect a patient’s upper limb symptom
alleviation. The electrical field was shaped using 16 different current fractionation
settings, four of which were bilateral monopolar settings and the remaining 12 having
employed current steering either unilaterally or bilaterally. This section will discuss the
results from the two objectives, present limitations and future directions of the study, and
end with concluding remarks.
4.1

Discussion of objective #1

The first objective was to determine the setting and amplitude that optimally alleviates
each patient’s upper limb symptoms. Given the variations in lead position, symptom
phenotype, and anatomical factors across patients, it was predicted that the benefits of
current steering and/or monopolar stimulation will differ among patients. Kinematic data
was used to quantify postural tremor, rest tremor, and bradykinesia, from which weekly
optimal settings were computed for the left and right upper limb of the seven patients
(Table 6). A notable observation from Table 6 is that the optimal settings change from
week to week for most patients. Recall that the two contacts chosen on each lead to
deliver current from stayed consistent across the study for all patients (Figure 7), and the
only variable that changed from week to week was the current amplitude. Thus, it can be
said that current amplitude influences the electrical field shape created by the current
fractionation setting. This is supported by a review of the technical features of DBS
systems which states that the current distribution, and therefore the electric stimulation
field, can be altered by the electrode design, the polarity and proportion of current
coming from each contact, and the amplitude of current (Amon & Alesch, 2017). Another
observation is that at week 4, all the optimal settings employed current steering either
unilaterally or bilaterally. This may suggest that at higher amplitudes, there is a larger
spread of current to neighboring structures and steering the current away from these
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structures is needed for optimal symptom alleviation. This phenomenon is supported by
the case study alluded to in section 1.2.5.1; further increasing amplitude on the
monopolar stimulation through contact #2 induced dyskinesia and was not sufficient to
control the patient’s tremor (Barbe et al., 2014). As a result, the stimulation field was
adjusted to a ‘tear drop shape’ by shifting stimulation toward a more proximal contact
and amplitude was slowly increased for improvement in motor symptoms without
causing dyskinesia (Barbe et al., 2014).
Table 6 also highlights 14 optimal settings, at the corresponding week’s amplitude, that
optimally alleviated each patient’s left and right upper limb symptoms among the four
weeks. Symptom alleviation at the 14 optimal states was significantly different from
symptoms quantified at the OFF state of all patients (Figure 15). This suggests that at the
optimal setting and amplitude, the electrical field shape was able to localize the current to
the target region in the STN. Eight out of the 14 optimal settings employed current
steering either unilaterally or bilaterally whereas the remaining six were bilateral
monopolar settings. As previously mentioned, monopolar settings create a relatively
spherical electrical field (Barbe et al., 2014). Therefore, we can assume that the optimal
states that involved a bilateral monopolar setting were able to create a spherical electrical
field around the active contact on both sides of the brain, at a specific amplitude, that was
able to stimulate the target region. Likewise, it can be assumed that the optimal states that
involved the use of current steering either unilaterally or bilaterally created an electrical
field shape, that was non-spherical and extended over two active contacts, which was
able to stimulate the target region. This suggests that the active contacts of the leads that
employed current steering was not within the optimal target region since optimal
alleviation could not be achieved with monopolar stimulation. Failure of the active
contacts to be within the target region could be due to the many reasons that lead to
suboptimal lead position in the brain (section 1.2.6) or anatomical factors that vary from
patient to patient, resulting in differences in functional target. It can be challenging to
study the variations in anatomy of basal ganglia nuclei across patients, which is usually
approached in two ways: in vivo imaging studies and postmortem studies. One MRI
study on 148 healthy adults ranging in age from 18 to 77 years old showed a bilateral
age-related shrinkage (in volume) of the head of the caudate nucleus and the putamen in
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both sexes (Gunning-Dixon, Head, McQuain, Acker, & Raz, 1998). In the same study, a
mild bilateral age-related shrinkage of the globus pallidus was only observed in men.
Although this study did not look at the size of the STN, the implications of age-related
changes in the neostriatum of healthy adults can be extended to a sample of diseased
patients. Variations in the shape or size of the STN across PD patients can affect optimal
anatomical targeting during DBS. A postmortem study measured the centers and borders
of the STN in relation to the anterior commissure-posterior commissure (AC-PC) line in
12 postmortem brains of patients who died of non-neurological diseases, ranging from 29
to 84 years of age (den Dunnen & Staal, 2005). The study showed that with a relatively
constant length of the AC-PC line, the center of the STN tends to move 3.9 mm cranially,
2.6 mm laterally and 0.2 mm anteriorly with increasing age. This change is thought to be
caused by the loss of neurons, however the extent to which neuronal loss occurs in the
STN at different ages is unknown (den Dunnen & Staal, 2005). Again, the age-related
changes can be applied to PD patients whose subthalamic nuclei can vary in shape and
spatial position, affecting optimal target determination during DBS. Within limits, current
steering may address this issue by allowing stimulation to be directed toward the
functional target, even if lead position is seemingly optimal based on pre-operative MRI
and stereotactic atlases.
4.1.1

Involvement of the ipsilateral STN

Some weekly optimal settings involved current steering at the STN that was ipsilateral to
the limb of interest (settings in purple in Table 6). This phenomenon is of interest because
conventionally it is known that movement of limbs is controlled by the contralateral side
of the brain. Specifically, upper limb muscles are mainly under the control of crossed
corticospinal projections originating from contralateral motor areas, including the basal
ganglia (Davare, Duque, Vandermeeren, Thonnard, & Olivier, 2007). This idea puts to
question why shaping of the electrical field is necessary at the ipsilateral STN if the target
region of a limb is the contralateral STN. Previous studies involving unilateral STN DBS
also suggest a similar finding; mild but sufficient improvement is observed in the
extremities ipsilateral to the stimulating electrode. For instance, Tabbal et al. used
objective kinematic measures to show improvement in ipsilateral motor function in 52
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PD patients who underwent unilateral STN DBS at a median of 8.7 months before testing
(Tabbal et al., 2008). Investigating the reasons for ipsilateral clinical benefit from
unilateral DBS may help to explain the need for targeted stimulation of not only the STN
contralateral to the limb, but also the ipsilateral STN. A potential explanation for this
phenomenon lies in the effects of brain lateralization on motor control.
4.1.2

Lateralization of motor control

Specific brain functions are mainly controlled by one hemisphere, a phenomenon known
as lateralization (or hemispheric dominance); the right hemisphere is dominant for spatial
cognition, body schema, proprioceptive control, and action inhibition, whereas the left
hemisphere is dominant for verbal processing and motor control (Lizarraga et al., 2017).
In 90% of humans that are right-handed, the left-sided dominance of motor control is
clear, whereas in left-handed and ambidextrous humans, brain asymmetries are less
obvious and it is unclear which hemisphere is dominant (Lizarraga et al., 2017). Although
the mechanism of lateralization for motor control is unknown, it has been proposed that
the left hemisphere controls limb trajectory and timing aspects of ballistic and sequential
movements, whereas the right hemisphere controls final limb position and posture
(Lizarraga et al., 2017). Additionally, the right inferior frontal cortex and STN contribute
to motor inhibition through suppression of thalamocortical signals. This idea of
lateralization can therefore be used to explain why stimulation parameters also affect the
STN that is ipsilateral to the targeted limb. In a right-handed PD patient with left-sided
dominance, stimulation of potentially lateralized motor circuits in the left hemisphere
could be necessary for optimal symptom alleviation in both the right and left upper limbs.
In addition, if the active contacts on the right lead are in proximity to potentially
lateralized circuits that contribute to motor inhibition as mentioned above, current
steering could address this issue by avoiding stimulation to these areas in the right
hemisphere for optimal symptom alleviation of both the right and left upper limbs.
Furthermore, Walker et al. used intraoperative microelectrode recordings of the STN in
patients with advanced idiopathic PD during unilateral DBS of the contralateral STN to
show that therapeutic 160 Hz unilateral stimulation results in increased activity in the
contralateral STN (Walker et al., 2011). This shows that unilateral STN stimulation
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activates bilateral basal ganglia networks, further adding to the idea that stimulation
parameters need to be tailored to the left and right nuclei for optimal symptom alleviation
of a limb, to avoid under- or overstimulation of potentially lateralized motor circuits.
4.2

Discussion of objective #2

The second objective compared the optimal alleviation of hyperkinetic symptoms, which
include upper limb rest and postural tremor, to optimal alleviation of hypokinetic
symptoms, which include upper limb rigidity and bradykinesia; it was predicted that
hyperkinetic symptoms will be optimally alleviated by settings that differ from those that
optimally alleviate hypokinetic symptoms in the same limb. UPDRS-III subscores were
used to quantify postural tremor, rest tremor, rigidity and bradykinesia, from which
weekly optimal settings were computed for the left and right upper limb of the seven
patients (Tables 7-10).
There were 107 instances where the same setting was able to optimally alleviate
hyperkinetic and hypokinetic symptoms of a limb (Table 11). There were 232 instances
where a setting was able to only optimally alleviate the hyperkinetic symptoms of a limb
(Table 12). Finally, there were 117 instances where a setting was able to only optimally
alleviate the hypokinetic symptoms of a limb (Table 13). These results suggest that there
are spatially separate regions for the alleviation of hyperkinetic and hypokinetic regions;
however, the settings involved in the instances of simultaneous optimal alleviation of
hyperkinetic and hypokinetic symptoms created electrical field shapes, at the
corresponding week’s amplitude, that were potentially able to target both regions.
Although the sensorimotor STN is conventionally used as the target for many DBS
surgeries for PD, as was the case for patients in this study, the tripartite functional
organization (Figure 2) is an oversimplification and may even be a topic of debate among
proponents. Alkemade and Forstmann argue that the current hypothesis of the three
subdivisions is based on low numbers of clinical observations and primate tracing
studies, and support a view that the topological organization within the nucleus does not
contain strict anatomical boundaries (Alkemade & Forstmann, 2014). Even if one holds
the assumption of functional specialization, the segregated sensorimotor, associative, and
limbic regions show substantial areas of overlap (Accolla et al., 2016). Therefore, the
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exact location of leads within the STN for optimal control of different symptoms is
continuously being studied.
4.2.1

Optimal tremor control

Current hypotheses regarding tremor generation in PD point to abnormal synchronization
of neuronal firing in the basal ganglia thalamocortical loop (Figure 4). Although resting
tremor usually responds successfully to STN-DBS, severe tremor and coexisting essential
tremor may progressively worsen with time (Mirza et al., 2017). Ventral intermediate
nucleus of the thalamus (Vim) DBS has been shown to suppress tremor more effectively
in tremor-dominant PD; however, proximal postural tremor, distal intention tremor and
some cerebellar outflow tremor is difficult to be well controlled by even Vim DBS (Xie,
Bernard, & Warnke, 2012). To address these issues, the posterior subthalamic area (PSA)
has been proposed as a target site because of promising results in tremor suppression. The
PSA consists of the zona incerta (Zi) and the prelemniscal radiation (Raprl), and is
bounded anteriorly by the posterior border of the STN and superiorly by the ventral
thalamic nuclei (Xie et al., 2012). The caudal Zi is an effective target for all forms of
tremor because of its unique GABAergic connections with the basal ganglia and
cerebellar thalamocortical loops (Xie et al., 2012). Given that the STN is relatively small
with its 5.9 mm x 3.7 mm x 5 mm dimensions and current spread is estimated to be 2-3
mm from the electrode for intensities of 2-3 mA, stimulation of neighboring structures
seems probable (Alkemade et al., 2017; Jankovic & Tolosa, 2015). Looking at the
breakdown of settings that only optimally alleviated hyperkinetic symptoms (Table 12),
we see that approximately 78% of the 232 total instances employed current steering
either unilaterally or bilaterally; the electrical field shapes created by these settings, at the
corresponding week’s amplitude, could have potentially steered current to the caudal Zi
for tremor suppression, especially in patients that had significant postural tremor. At
week 2, there is a significant difference between instances that contained bilateral
monopolar settings and settings that employed current steering at the STN contralateral
(df = 1, p < 0.05) and ipsilateral (df = 1, p < 0.05) to the limb of interest. The greater
number of occurrences involving bilateral monopolar settings may have contributed to
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spherical electrical fields surrounding the active contacts for local stimulation in the STN
for optimal suppression of resting tremor.
4.2.2

Optimal control of rigidity and bradykinesia

Rigidity and bradykinesia respond well to both STN and GPi DBS, however the exact
location within these nuclei for optimal control needs further investigation (Mirza et al.,
2017). There is evidence to show that stimulation of the Raprl could reduce rigidity as
well as contralateral tremor (Xie et al., 2012). The Raprl is a fiber bundle that lies
posterior to the STN, separated from it by the Zi; it consists of fibers that project to the
thalamus as well as ascending cerebellothalamic fibers (Xie et al., 2012). A study by
Velasco et al. on 10 PD patients who underwent unilateral Raprl electrical stimulation
showed significant improvement in tremor and rigidity, with mild improvement in
bradykinesia (Velasco et al., 2001). Additionally, another study showed chronic Raprl
electrical stimulation induced a significant decrease in tremor and rigidity in 14 PD
patients (Jimenez et al., 2000). The aforementioned studies are of importance to the
results seen in Table 11 showing 107 instances where the same setting worked to
optimally alleviate hyperkinetic and hypokinetic symptoms in the same limb. The
electrical field shapes created by these settings, at the corresponding week’s amplitude,
may have potentially reached the Raprl where optimal control of tremor (hyperkinetic)
and rigidity (hypokinetic) can be achieved. Given that the Raprl is a non-spherical fiber
bundle, it can be difficult to optimally capture with spherical stimulation geometries
(Schüpbach et al., 2017); this can explain why approximately 76% of the 107 instances of
simultaneous optimal alleviation of hyperkinetic and hypokinetic symptoms employed
current steering either unilaterally or bilaterally. There was also a significant difference
between instances involving settings that employed current steering at the STN ipsilateral
to the limb and those that employed current steering at the STN contralateral to the limb
(df = 1, p < 0.05). The greater number of instances involving current steering at the
ipsilateral STN could point towards the effects of lateralization discussed in section 4.1.2,
where lateralized motor circuits controlling hyperkinetic and hypokinetic symptoms
could have potentially been the target of stimulation.
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4.3

Implications and clinical relevance

The current study’s findings can be used to contribute to the advancement of PD
symptom management. To start off, the optimal settings outlined in Table 6 are the result
of an objective quantification using an IMU-based sensor system, as opposed to a
relatively subjective interpretation using UPDRS-III subscores. From these results, it can
be concluded that implanting a constant-current DBS system that is capable of current
steering is potentially more beneficial to the patient than implanting a voltage-controlled
single source system given that more than half the 14 optimal settings employed current
steering either unilaterally or bilaterally. Factors such as suboptimal lead positioning,
differences in functional target due to symptom heterogeneity, and anatomical variations
between patients cannot be predicted before surgery to guarantee that a patient will
optimally benefit from a monopolar setting creating a spherical electrical field around the
active contact. Therefore, having the flexibility to program a uniform, non-spherical
electrical field allows the patient to receive optimal treatment despite the external factors
mentioned above. Although the optimal settings in Table 6 were only quantified for the
upper limb, the findings can be extended to whole-body quantification; from the optimal
settings determined by a whole-body UPDRS-III score that each patient went home with
at the study conclusion (Table 5), only one patient went home with a bilateral monopolar
stimulation. Furthermore, the results of the second objective provide insight into the use
of current steering in alleviating PD symptom subtypes. The fact that there were more
instances where settings were able to optimally alleviate only hyperkinetic symptoms of a
limb (Table 12) or only hypokinetic symptoms of a limb (Table 13), compared to
instances where the same setting was able to optimally alleviate hyperkinetic and
hypokinetic symptoms of a limb (Table 11) shows that there are different electrical field
shapes, and by extension potentially different targets, for optimal alleviation of different
symptom subtypes. Therefore, clinical follow-up could focus on using similar
programming parameters in subsets of patients based on similar symptom phenotype;
future studies are needed to support this.
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4.4

Limitations

One of the most prominent limitations of this study is the low sample size; an n-value of
seven is not an accurate representation of the PD population as there are varying disease
phenotypes that extend well beyond the tested sample. In addition, statistical power could
be increased with a larger sample size to have more conclusive outcomes. Another
prominent limitation is that there is not a testable way to show how the geometry of the
electric field inside the brain is being changed by current steering; a close alternative
would be mapping electric field simulations on post-operative MRI scans that show
localization of electrodes within the STN. Using ultra-high resolution 7 T MRI to show
which area within the nucleus is being targeted can also be used to corroborate the
understanding of functional subdivision in the STN. Other limitations of the study were
constraints of time and feasibility, such as being able to test only 16 different settings, not
being able to replicate a testing session at a different time point, and the lack of agematched healthy control data. The different possibilities of current fractionation are
infinite (e.g. current can be fractionated between two contacts using an 80%-20% split,
60%-40% split, 55-45% split, etc.), but due to the constraints of time and preventing
patient fatigue, a maximum of four settings were tested each day. Being able to replicate
patient performance at a setting and amplitude at a different time point and extending to a
longitudinal study that follows the course of treatment over a few months, can increase
the reproducibility of the study. Normalization of kinematic values for this study was
achieved using data from neurologists who were used as healthy participants and who
also mimicked performance of a severe PD patient; using values from age-matched
healthy controls and advanced PD patients with severe motor symptoms could increase
the validity of the study.
4.5

Future directions

To address some of the limitations in this study, future studies could look at the
correlation between the use of current steering in optimal symptom alleviation and
electrode localization in the STN using imaging techniques. A deeper investigation into
different electrical field shapes can also be explored by testing different combinations of
current fractionation, and even investigating the effects of current steering in horizontal
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directions. The latter would require implanting directional leads for DBS and contributing
to the limited literature on the utility and effectiveness of steering the stimulation field in
the plane perpendicular to the lead. Another follow-up study would be to look at the
effects of current steering on axial symptoms and perform a comparison to see if there are
settings that work optimally for appendicular and axial symptom improvement.
Additionally, closely monitoring disease phenotype pre- and post-DBS treatment could
have significant clinical implications. Categorizing patients according to their symptoms
such as being tremor-dominant or bradykinesia-dominant and looking at the effects of
current steering on these subsets of patients can eliminate some of the programming
challenges clinicians face during patient follow-up.
4.6

Conclusion

In summary, the current thesis showed that manipulating the shape of the electrical field
in PD patients who underwent STN-DBS using current steering affected the degree of
upper limb symptom alleviation. Kinematic data was used to show that the use of current
steering in optimal upper limb symptom alleviation is highly individualized and is not
only patient-dependent but also limb-dependent. Current steering may address issues of
lead misplacement and possible anatomical differences by directing the stimulation field
to the target region. This study also used UPDRS-III subscores to contribute to the
growing evidence for areas that individually control tremor and hypokinetic symptoms.
Current steering may also contribute to instances of simultaneous alleviation of
hyperkinetic and hypokinetic symptoms by shaping the electrical field to optimally
capture areas that control both symptom subtypes. Limitations of this study include a low
sample size and being unable to detect which subarea of the STN was being stimulated
by the different settings. Future directions should be aimed at mapping electric field
simulations on high resolution MRI scans that show electrode location so that more
robust conclusions about functional targets can be made.
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Appendix 4: Electrode Localization
BSC 02

R

L

Superior/posterior view of electrode localization. Green mass represents implanted
macroelectrode (lead), pink rings represent active contacts chosen for stimulation,
microelectrode recordings represented as tracks surrounding each lead with red cylinders
representing subthalamic nucleus (STN) location. L: left STN; R: right STN

L

Closer look showing both contacts
are within the left STN (red cylinder).

R

Closer look showing both contacts
are within the right STN (red cylinders).
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BSC 03

L

R

Superior/posterior view of electrode localization. Green mass represents implanted
macroelectrode (lead), pink rings represent active contacts chosen for stimulation,
microelectrode recordings represented as tracks surrounding each lead with red cylinders
representing subthalamic nucleus (STN) location. L: left STN; R: right STN

L

R

Closer look shows only the more ventral
Closer look showing both contacts are
contact is within the left STN (red cylinder). within the right STN (red cylinders).
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BSC 05

L
Left lead (green) showing active contacts (purple) are within the left STN (red cylinder).
More dorsal contact is mostly outside the STN.

R
Only the more ventral active contact is within the right STN (red cylinder).
More dorsal contact is outside the STN.
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BSC 06

L

R

Superior/posterior view of electrode localization. Green mass represents implanted
macroelectrode (lead), pink rings represent active contacts chosen for stimulation,
microelectrode recordings represented as tracks surrounding each lead with red cylinders
representing subthalamic nucleus (STN) location. L: left STN; R: right STN

L
Closer look showing both contacts
are outside the left STN (red cylinders).

R
Closer look showing both contacts are
outside the right STN (red cylinders).
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BSC 07

R

L

Superior/posterior view of electrode localization. Green mass represents implanted
macroelectrode (lead), pink rings represent active contacts chosen for stimulation,
microelectrode recordings represented as tracks surrounding each lead with red cylinders
representing subthalamic nucleus (STN) location. L: left STN; R: right STN

L
Closer look showing both contacts
are within the left STN (red cylinders).

R
Closer look showing both contacts
are within the right STN (red cylinder).
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